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Summary 
This study focuses on the apparently distinct roles of various checkpoint 
associated kinases including ATM, ATR, and CHK1 in bladder cancer 
compared with normal human urothelial (NHU) cells. The primary signalling 
cascade that responds to replication stress in bladder cancer cells (ATR-CHK1) 
is deficient in normal urothelial cells after treatment with a replication inhibitor 
and these cells do not depend upon CHK1 for protection from apoptosis during 
replication stress. This is very different from the situation in bladder cancer 
cells, where ATR-CHK1 plays a prominent role. Instead ATM signalling is more 
rapidly activated under these conditions. Intriguingly, an ATM inhibitor 
suppressed S-phase checkpoint activation after exposure to replication 
inhibitors and stopped entry of hTERT-NHU cells into S-phase with G1 
accumulation of cells suggesting activation of a G1 checkpoint. Consistent with 
this, cells treated with the ATM inhibitor and thymidine showed increased 
levels of cyclin-dependent kinase inhibitor p19 INK4D, reduced levels of cyclin D1 
and CDK4, and reduced phosphorylation of the retinoblastoma (RB) protein. In 
contrast, a bladder cancer cell line treated with the ATM inhibitor progressed 
more slowly through S-phase and showed a dramatic increase in apoptosis 
following co-treatment with ATM and replication inhibitors. Taken together, 
  
5 
 
these findings suggest that ATM and CHK1 signalling cascades play different 
roles in tumour and normal epithelial cells, confirming these as promising 
therapeutic targets. 
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Chapter 1 Introduction 
1.1  Cancer 
Cancer is a large family of genome diseases and one of the most serious 
health threats facing the world today. So far more than 200 distinct types of 
cancer have been determined. In addition, cancer can develop in any organ 
from almost any type of cell in over 60 different body parts. In general, cancer 
can be classified into three categories by the cell types of cancer development 
and further classified according to tissue of origin. Most of human cancers 
(about 90%) are malignancies of epithelial cells which are considered as 
carcinomas. The tumours of supporting tissues such as bone, cartilage, fat, 
connective tissue, muscle are sarcomas. These types of cancer are much 
more rare than carcinomas. Furthermore, human cancers originating from cells 
of blood & lymphatic origin are called leukemias and lymphomas and make an 
about 8% of all malignancies. The causes of cancer are diverse and complex. 
In the beginning, there are six hallmarks of cancer have been identified: 1. 
self-sufficiency in growth signals, 2. insensitivity to anti-growth signals, 3. 
evading apoptosis, 4. limitless replicative potential, 5. tissue invasion and 
metastasis, 6. sustained angiogenesis (Hanahan and Weinberg, 2000).  
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 Self-sufficiency in growth signals: It is generally accepted that normal cells 
require mitogenic growth signals for active proliferation from external 
surrounding. There is no type of normal cell that can keep proliferating in 
the absence of these growth signals. However many of the oncogenes in 
cancers were found to act as growth signals for their own proliferation. 
 Insensitivity to anti-growth signals: In contrast to growth signals, there are 
also multiple anti-proliferative signals and mechanisms which are able to 
operate to maintain cellular quiescence for preventing uncontrolled growth 
within normal cells. For instance, transforming growth factor-beta 
(TGF-beta) was reported to inhibit cell proliferation by inducing a 
G1-phase cell cycle arrest (Hannon and Beach, 1994). It is not surprising 
that cancer cells have developed mechanisms to evade those kinds of 
growth control. 
 The evasion of apoptosis: Apoptosis, programmed cell death, is a critical 
mechanism to eliminate damaged or mutated cells which can not be 
repaired. It also represents a major source of cell attrition to control the 
cell number in tissues to avoid unlimited cell proliferation. Hence 
malignant tumour cells must therefore develop a means to avoid both 
intracellular and extracellular apoptosis signals. 
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 Unlimited replicative potential: Cell proliferation is strictly limited in normal 
cells. For instance, normal human cells carry an intrinsic finite replication 
limitation that relies on this shortening of their chromosome telomeres 
after cell mitosis. However telomerase, the enzyme which is able to 
maintain the length of telomere is re-activated in cancer cells. Most 
tumour cells in culture are immortalized suggesting that this limit of 
replicative potential does not exist in cancer cells. 
 Tissue invasion and metastasis: Most types of human cancer cells are 
able to migrate to adjacent or distant sites and invade surrounding tissues 
from primary tumour site during early or later development stage. 
Although the mechanisms and details remain incompletely understood, 
the affected proteins include cell–cell adhesion molecules (CAMs) and 
extracellular proteases. These newly formed metastases are the causes 
of 90% of cancer death. 
 Sustained angiogenesis: Unlike vasculogenesis which is the de 
novo formation of blood vessels (Risau and Flamme, 1995), angiogenesis 
refers to the process of new formation of blood vessels from pre-existing 
ones. The oxygen and nutrients carried by the vasculature are essential 
for cell growth and survival in both normal and malignant cells. Thus, in 
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order to progress to a larger size, angiogenesis is necessary for tumour 
cells.  
 
Recently, these hallmarks of cancer were underlined as genome instability 
which generates the genetic diversity and further advances cancer 
development. For instance, mutated and constitutively activated growth factor 
receptors activate additional downstream signalling transduction such as 
Raf-MAPK pathway which participates in cell proliferation and invasion (Davies 
and Samuels, 2010). Null mutation occurring on tumour suppressor genes 
including Rb and TP53 results in tumour cells evade growth suppressors 
(Ghebranious and Donehower, 1998; Lipinski and Jacks, 1999). Furthermore, 
TP53 induces apoptosis by up-regulating expression of the pro-apoptotic 
triggering proteins such as Bax and Bak in response to DNA damage (Adams 
and Cory, 2007), thus loss of functional TP53 enable tumour cells to resistant 
cell death from stress.  
 
In the past decade, two enabling characteristics such as “genome instability” 
including random mutations and chromosomal rearrangements and 
“tumour-promoting inflammation” have also been identified as cancer 
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hallmarks which contribute to tumour progression and development. 
“Deregulating cellular energetic” and “avoiding immune destruction” are 
another two newly identified hallmarks of cancer, which involve in cellular 
metabolism or re-programme to neoplastic proliferation and to evade 
immunological destruction particularly by T and B lymphocytes, macrophages, 
and natural killer cells (Hanahan and Weinberg, 2011). So far, there are 
currently 10 typical hallmarks of cancer have been identified.   
 
FIGURE1. The hallmarks of cancer (Hanahan and Weinberg, 2011) 
 
      
 
8 
 
Additionally, whereas the molecular basis of genomic instability in sporadic 
cancers is still unclear, mutations in DNA repair genes have been considered 
to result in genomic instability and further leading to cancer development in 
hereditary cancers. In hereditary cancers genomic instability is considered as 
the initial event, which further contributes all the other hallmarks. However, 
deregulation of growth signalling may be the initiating event in sporadic 
cancers. Deregulation of growth-regulating genes leads to DNA damage and 
replication tress and then causes genomic instability. The mutation occurring 
on tumour suppressor genes such as TP53, ATM and CDKN2A not only 
contributes genomic instability but also demonstrated to induce DNA damage 
(Negrini et al., 2010).  
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FIGURE1.1 Genomic instability in hereditary and sporadic cancer 
(Negrini et al., 2010) 
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1.1.1  Cancer Statistics 
It has been reported form a statistical study of cancer research UK that 
malignant tumours are the leading cause of death around the world. More than 
8.2 million people died because of cancer worldwide in 2012. Approximately 
331,000 new cancer cases are projected to occur, resulting in over 161,000 
deaths in the United Kingdom in the same year. Seriously, it is estimated that 
more than one in three people in the UK will develop some form of cancer 
during their lifetime. The incidence rates for all cancers combined have largely 
increased by 23% in males and 43% in females since mid-1970s in the UK. In 
other words, cancer is one of the leading death threats nowadays.  
 
1.1.2 Bladder Cancer 
Bladder cancer refers to any of several types of malignant tumour arising from 
the urinary bladder which is the organ that collects urine excreted by 
the kidneys . About 90% of bladder cancers are transitional cell carcinoma 
(TCC or called urothelial cell carcinoma, UCC). Cancer arises and develops 
from the cells of the inner surface of the bladder. Among all the cases of 
various cancers, urinary bladder tumour is ranked as the fourth most common 
cancer with over 7,000 new cases and the six highest cause of death resulting 
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in more than 3,400 deaths among British males in 2011. Notably, the risk of 
developing bladder cancer of men is about 2.5 times higher than that in 
women.  
 
1.1.2.1 Risk Factor 
Risk factors are influences that change the likelihood of developing a disease 
such as cancer. There are many known risk factors associated with bladder 
cancer. In other words, bladder cancer is the end result of the variable 
combination of risk factors. Cigarette smoking is one of the major risk factors 
for bladder cancer due to the fact that more than 50% of bladder cancer 
population in men and 30% in women are accounted with smoking habit 
(Kakehi et al., 2010). Workplace exposures also result in cancer. For example, 
being around certain chemicals used in the manufacture of dyes, rubber, 
leather, textiles and paint products increases the risk of bladder cancer. 
Exposure to arsenic in drinking water at concentrations higher than 300 µg/l is 
also strongly associated with bladder cancer (Letasiova et al., 2012). In 
addition, certain industrial chemicals called aromatic amines, such as 
benzidine and beta-naphthylamine have also been reported to cause bladder 
cancer (Ferrís et al., 2013; Letasiova et al., 2012). Age and gender are other 
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risk factors for developing bladder cancer. Bladder cancer occurs more 
commonly in the elderly population and shows a 4:1 ratio of males to females 
(Ferrís et al., 2013; Shariat et al., 2010).  
 
The most important of all, variant genetic polymorphisms associate with 
bladder cancer have been revealed recently. Single nucleotide polymorphism 
(SNP) in CDKN2A intronic region has been implicated in the pathogenesis of 
bladder cancer (Li et al., 2014). Genetic variation in TP63C/T, TERTC/T, and 
SLC14A1C/T were also confirmed associated to bladder tumour in European 
and White population. Multiple SNPs in base excision repair system including 
XRCC1 modulate the risk of bladder cancer, which modify survival of bladder 
cancer patients treated with chemotherapy (Sacerdote et al., 2013; Xie et al., 
2013). However, individual prediction of disease outcome based on “molecular 
markers” of bladder cancer is currently not reliable. Due to reproducibility 
issues, these markers are not yet used in the daily clinical routine even they 
are considered to predict progression and survival (but not recurrence) (van 
Rhijn et al., 2014). Reproducibility of marker assessment and consistency of 
examine results needs more studies in the future.  
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1.1.2.2 Bladder Cancer Stage 
The stage of cancer is based on how big the tumour is and how far it has 
spread. The most common system to describe cancer stage is the TNM 
(Tumour, Node, Metastasis) system which is available for all cancers. T stands 
for how deeply the tumour has grown. N indicates whether there is cancer 
found in lymph nodes and M means whether the tumour cells have spread to 
any other area of body. Combined with the number staging system, the 
development of cancer is well defined and makes it much easier to decide the 
correct treatment options. In general, the number staging system is usually 
classified into four main stages. Stage 1 is the most benign of cancer and 
stage 4 is the most advanced stage. 
  
1.1.2.2.1  The T stages of bladder cancer (See Fig.1.1) 
 T0 – no evidence of a primary tumour 
 CIS (also called Tis) – in situ carcinoma, tumours are only in the deepest 
layer of the bladder lining  
 Ta – the tumours are non-invasive in the deepest layer of the bladder lining 
 T1 – the tumours have started to grow at the connective tissue below the 
bladder lining 
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 T2 – the tumours have grown through the connective tissue to the muscle 
 T2a – only superficial muscle involvement 
 T2b – deep muscle involvement 
 T3 – the cancer has extended beyond bladder wall 
 T3a – microscopic invasion, the tumours in the fat layer can only be 
observed by using a microscope  
 T3b – macroscopic invasion, the tumours in the fat layer are large enough 
that they can be observed on image tests, or felt during an examination 
under anaesthetic by a surgeon  
 T4 – the tumours have spread outside the bladder and into nearby organs 
or structures. 
 T4a – the tumours have invaded to neighbouring structures such 
as prostate, uterus or vagina 
 T4b – the tumours have spread to the wall of the pelvis or abdomen 
(Fig.1.1) 
 
This system is defined according to a combination of the test of cancer cells 
after a biopsy, inspection of the bladder performed by anaesthetic surgeon and 
a CT or MRI scanning (Cancer Research UK). 
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FIGURE1. 2. The T stage of bladder cancer. (Action on Bladder Cancer) 
 
1.1.2.2.2  The N Stage of Bladder Cancer 
The N category describes whether the cancer spreads to the lymph nodes 
near the bladder. Like the T stage of bladder cancer, there are four lymph node 
stages defined in bladder cancer as well. CT or MRI scan is able to see and 
measure the lymph nodes, or they may be found during the surgery for 
removing bladder. 
 N0 – no cancer is found in any lymph nodes 
 N1 – tumour is found in only one lymph node in the pelvis 
 N2 – tumour is found in more than one lymph node in the pelvis 
 N3 – tumour is found in one or more lymph nodes in the groin 
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1.1.2.2.3  The M Stage of Bladder Cancer 
If there is no sign of any cancer invading to another body organ, it marks as M0. 
In contrast, M1 indicates that the cancer has spread to distant areas of the 
body. Bones, lungs, liver and distant lymph nodes are the most common sites 
of bladder cancer metastases. 
 
1.1.2.2.4  The Grade of Bladder Cancer 
In addition to cancer stages, the term “tumour grade” means how well the 
cancer cells developed (Cancer Research UK). 
 Low grade cancers – they look very much like normal cells and are well 
differentiated and growing slowly 
 Medium grade cancer cells – they look abnormal and are moderately 
differentiated and more likely to spread into the muscle layer of the bladder 
or to recur after treatment 
 High grade cancer cells – they look extremely abnormal and are high 
graded and poorly differentiated. These tumours grow quickly, are more 
likely to recur after treatment and more likely to invade into the muscle of 
bladder 
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Additionally, the World Health Organization (WHO) has developed a new 
classification system for bladder cancer in 2004, which divides the cancers into 
four categories: 
 Urothelial papilloma – the tumour is non cancerous (benign)  
 Papillary urothelial neoplasm of low malignant potential (PUNLMP) – the 
tumour grows very slowly and unlikely to spread 
 Low grade papillary urothelial carcinoma – the tumour grows slowly and 
unlikely to spread 
 High grade papillary urothelial carcinoma – the tumour grows more quickly 
and more likely to spread 
 
1.1.2.3 Treatment of Bladder Cancer 
Treatments for cancer of the bladder are generally classified as four main 
types: Surgery, intravesical therapy, chemotherapy and radiation therapy.  
Surgery is the main and may be recognised the most successful treatment for 
most solid tumours including bladder cancer. Recently, the gold standard for 
the detection of bladder cancer has been considered as conventional or 
white-light cystoscopy. However, it is difficult to examine flat lesions such as 
cancer in situ with this technique and the disadvantage can further result in 
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incomplete tumour resection (Jacobs et al., 2010). With intravesical therapy, 
the medicine is directly administrated into the bladder rather than given by 
mouth or injected into a vein. This increases the likelihood that only tumour 
cells in bladder will be affected by medicine. Any cancer cells outside of the 
bladder or have grown deeply into the bladder wall are not treated. Medicines 
administrated into the bladder are not able to reach cancer cells in other 
organs such as kidneys, ureters, and urethra. Currently, radiation and 
chemotherapy are two major cancer treatments of bladder tumour (Kaufman et 
al., 2009). Nevertheless, it is a problem that the recurrence is still high 
(Soloway et al., 2002). Of newly diagnosed bladder cancer cases, although 
almost a quarter will present with non-muscle-invasive diseases and are not 
death threatening, however more than half of the patients will show the 
recurrences and most of those will be within five years (Sylvester et al., 2002). 
Furthermore, approximately 30% of cases will progress to muscle-invasive 
cancers and result in life threatening from distant metastases (Saad et al., 
2002). 
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1.2 Cell Cycle Regulation and Cancer 
1.2.1 The Cell Cycle 
The cell cycle, or cell-division cycle refers a process of cellular events that 
occur in a cell associating with its duplication and division, which leads to the 
production of two daughter cells. The cell cycle consists of four phases G1 
(gap), S (synthesis), G2 phase and M (mitosis). In G1 phase, the proteins for 
DNA replication are synthesized. During S phase, the cell increases its size 
and DNA replication occurs. G2 is the gap between DNA synthesis and mitosis. 
Cells continue to grow in this stage. Everything for M phase and cell division is 
prepared and confirmed ready before entering M phase. Finally, cell growth 
stops at M phase. Two identical daughter cells are derived from one single cell 
and re-enter G1 phase again.   
 
1.2.2 Cell Cycle Control 
Cell cycle progression is an accurate mechanism which is well-controlled by 
specific holoenzymes made up of the regulatory cyclins and catalytic 
cyclin-dependent kinases (CDKs). The specific cyclins and corresponding 
CDKs can form complexes called cyclin-CDK (cyclin-dependent kinases) 
complexes resulting in the activation of CDKs. In 2001, Timothy R Hunt, Paul 
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M Nurse and Leland H Hartwell shared the Nobel Prize in Physiology or 
Medicine for their discoveries of key regulators of the cell cycle (Balter and 
Vogel, 2001). In mammalian cells, these multiple CDKs and cyclins which 
regulate passage through the cell cycle can be classified to four main groups 
by the stage of cell cycle: 
 Mid G1: CyclinD-CDK4/6 
 Late G1: Cyclin E-CDK2 
 S phase: Cyclin A-CDK2 
 Mitotic phase: CyclinA/B-CDK1 
 
FIGURE1.3. The cell cycle progression. Multiple CDKs & cyclins regulate 
passage of mammalian cells through the cell cycle (taken from Molecular Cell 
Biology 5th edition). 
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1.2.3 Cell Cycle Control and Cancer 
As described previously, most cancer cells are derived from normal cells which 
show many alterations in signal transduction pathways leading to uncontrolled 
proliferation. Molecular studies have revealed that cell cycle regulators are 
frequently mutated in many human tumour cells. This indicates the importance 
of correct cell cycle regulation in cancer prevention. These aberrant 
regulations of cyclins and CDKs are advantage tumour cells to bypass the 
normal regulation resulting in uncontrolled cell cycle progression (Malumbres 
and Barbacid 2001). 
 
1.2.4 Cell Cycle Checkpoints 
It has been reported from the review article in Cancer Cell in 2003 (Bartek and 
Lukas, 2003) that losing cell cycle control causes accumulation of genetic 
aberrations which further results in transformation of normal cells to tumour 
cells and lead to tumourigenesis and carcinogenesis and eventually invasive, 
malignant cancers. When DNA damage or replication stress occurs, 
checkpoint systems are activated, which arrests cell cycle progression in order 
to have time for DNA repair or induce cell apoptosis to prevent the damage 
becoming worse. In mammalian cells, there are two highly conserved signal 
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transduction pathways with two key molecules: checkpoint kinase 1 (Chk1) 
and checkpoint kinase 2 (Chk2) which participate in checkpoint systems (Fig. 
1.3) to guarantee the genome stability and the accuracy of cell cycle 
progression such as the completed cell mitosis or DNA replication of the entire 
cell cycle (Bartek and Lukas, 2003).  
 
FIGURE1.4. Two conservative pathways involved in checkpoint systems. 
Chk1/2 respectively regulates different downstream proteins such as Mdm2, 
p53 and Cdc25 family and participates in checkpoint system. Red proteins are 
regulated by Chk2; Green one by Chk1; Blue ones by both (Bartek and Lukas, 
2003). 
 
Chk1 and Chk2 are structurally unrelated serine/threonine protein kinases, 
with overlapping function in the checkpoint signal transduction pathway. These 
two protein kinases have already been proven to trigger in response to various 
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stimuli (Bartek and Lukas, 2001; McGowan, 2002). Activation of Chk1 or Chk2 
relies on phosphatidylinositol 3-kinase family particularly ataxia telangiectasia 
and Rad3-related protein (ATR) and ataxia-telangiectasia mutated protein 
(ATM) (Abraham, 2001). These upstream PIKK proteins then activate and 
phosphorylate the two downstream crucial checkpoint kinases respectively. It 
is well accepted that while the ATM-Chk2 signalling cascade is activated 
mainly in response to DNA double strands breaks (DSBs), ATR-Chk1 
transduction pathway responds to DNA single strand lesions and especially 
DNA replication stress (Fig. 1.4).  
 
FIGURE1.5. Two conserved pathways involved in checkpoint systems. 
The ATM activates downstream Chk2 by phosphorylating Ser68 in response to 
DSBs whereas Chk1 is mainly activated by ATR with Ser345, Ser317 
phosphorylation following the presence of ssDNA. (Bartek and Lukas, 2003) 
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For example, ATR was proven to be activated in response to various genotoxic 
agents and chemicals which stall replication folks such as topoisomerase 
inhibitors and hydroxyurea (HU) (Melo and Toczyski, 2002).  
 
1.2.4.1 The G1 Checkpoint 
Since Chk1 kinase expression is restricted to S-G2 phases of the cell cycle, the 
major G1 checkpoint is governed by the ATM-Chk2-p53-p21 pathway to 
confirm all events occurring in G1 phase are correctly operated before entering 
S-phase (Lukas et al., 2001). DNA damage is detected by ATM which has 
been demonstrated to be able to activate the downstream tumour suppressor 
protein p53 (Banin et al., 1998). Activated p53 up-regulates p21 which is an 
inhibitor of CDK2 (Li et al., 1994) leading to the inhibition of CyclinE/CDK2 and 
delayed G1 phase progression. 
  
1.2.4.2 The Intra-S Checkpoint 
The intra-S checkpoint can be triggered in response to both DNA double 
strand breaks (DSB) and stalled replication fork-induced single strand DNA 
(ssDNA). Activated intra-S checkpoint results in Chk1/Chk2 activation leading 
to Cdc25A phosphorylation and trigger its degradation (Mailand et al., 2000) 
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which causes CDK2 to remain inactivated and unable to promote cell cycle 
progression through S phase. 
 
1.2.4.3 The G2/M Transition Checkpoint 
The G2/M transition checkpoint prevents mitotic entry in the presence of 
un-replicated DNA induced from previous cell cycle stage or DNA damages. In 
response to incomplete DNA replication or DNA lesions, ATR-Chk1 pathway 
phosphorylates Cdc25C, which targets it for transport out of the nucleus (Xiao 
et al., 2003) so that CDK1 remains inactivated and terminates G2/M 
progression. 
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1.2.5 The Two Highly Conserved Checkpoint Pathways  
1.2.5.1 Chk1 and Chk2 
It is commonly accepted that Chk2 acts as a stable protein which presents 
throughout entire cell cycle, however Chk1 is an unstable protein that its 
activation mainly restricts to both S and G2 phase (Lukas et al., 2001). Chk1 
kinase plays a role at S-G2/M phase transition of cell cycle even in undisturbed 
cell cycle in human fibroblasts without DNA damage (Kaneko et al., 1999). In 
addition, according to studies based on embryonic stem cells, Chk1 was 
demonstrated to play a crucial role for mammalian development and cell 
viability. Mice with Chk1 depleted and embryonic cells with Chk1 deficiency 
were lethal (Liu et al., 2000). However the Chk2-deficient mice were viable 
with normal features, and exhibited resistance to ionizing radiation (IR) without 
any enhanced level of tumourigenesis (Takai et al., 2002). Although Chk1 
knockout is not lethal in somatic cells, many cell types with Chk1 depletion 
grow slowly and accompany increased spontaneous apoptosis (Meuth, 2010). 
Furthermore, during DNA replication stress, siRNA-mediated Chk1 
suppression was showed to result in significant cell apoptosis (Myers et al., 
2009). These findings indicate the hypothesis that Chk1 plays a role protecting 
tumour cells from apoptosis induced by DNA replication defects.  
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1.2.5.2 The Mechanism of Chk1 in Cell Cycle Checkpoint 
In the past two decades, the potential mechanism of how Chk1 regulates S 
and G2 phase arrest was established. The checkpoint kinase regulates the 
activation of downstream Cdc25 phosphatases especially Cdc25A and 
Cdc25B which remove phosphates from inhibitory tyrosine and threonine 
residues of cyclin-dependant kinases (CDKs) are essential for cell cycle 
progression (Furnari et al., 1997; Sanchez et al., 1997). Afterward, the 
activated cyclin-CDK complex finally contributes cell cycle to further progress 
(Xiao et al., 2003) (Fig. 1.5). 
 
FIGURE1.6. Schematic representation of the effect of Chk1 on 
Cyclin-CDK complex regulation. Replication stress-activated Chk1 regulates 
CDC25A which removes the inhibitory phosphate from CDK, which promotes 
cell cycle progression. 
 
Intriguingly, Cdc25A, Cdc25B, but not Cdc25C have already been 
demonstrated to be over-expressed in many aggressive human cancer cell 
lines and recognised as proto-oncogenes (Wu et al., 1998). During the past 
few years, more mechanisms of Chk1 function have been further established. 
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As described previously, Chk1 is necessary to regulate the activation of 
replication origins via Cdc25 phosphatases in undisturbed S phase (Shechter 
et al., 2004). Furthermore, Chk1 has also been found to be required to 
maintain replication fork progression in vertebrate cells even without DNA 
damage (Petermann et al., 2006). According to In vitro siRNA-based 
experiments, it was reported that human Chk1 suppression also led to a 
transient increased initiation of DNA replication and DNA breakage i n human 
osteosarcoma (Syljuasen et al., 2005). Similarly, it was shown that even 
without external DNA replication defects, the cells treated with the specific 
Chk1 inhibitor alone also result in a delayed S phase progression in not only 
normal primary cells but also several cancer cell lines. Additionally, due to the 
fact that human beings have a large genome, there are approximately 50,000 
replication origins that can be used during S phase. From in vitro observations 
of vertebrate cells, Chk1 is also found to modulate the density of replication 
origin activation by inhibiting latent origin firing during undisturbed S phase 
progression (Maya-Mendoza et al., 2007). Therefore, it is not surprising that 
Chk1 kinase acts as a workhorse not only in damaged cells but also in normal 
undisturbed cells whereas nonessential Chk2 is conditionally activated in 
response to DNA damage. Altogether, these studies strongly indicate that 
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aberrant Chk1 function may play a crucial role in the progression and 
development of tumour transformation. 
 
1.2.6 Potential Applications of Chk1 in Cancer Therapy 
As described previously, cell cycle progression is a highly controlled process 
and accurately monitored by surveillance systems such as cell cycle 
checkpoints. Since Chk1 kinase is over-expressed in many types of tumours 
(Verlinden et al., 2007), Chk1 seems to play a role to protect cancer cells from 
cell apoptosis in response to the treatment of anti-cancer drugs. Since tumour 
cells commonly lack G1 checkpoint and rely on S and G2 checkpoints instead, 
this incident suggests a potential of novel cancer therapeutics with the 
combination of Chk1 inhibitors and radiotherapy or clinical anti-cancer drugs. 
For example, UCN-01 (7-hydroxystaurosporine) is widely recognised as a 
powerful but unselective Chk1 inhibitor (Graves et al., 2000). It has been 
reported to sensitize various cancer cells to variant DNA-damaging agents 
such as cisplatin (Wang et al., 1996), topoisomerase I inhibitors (Shao et al., 
1997) or gemcitabine (Shi et al., 2001). However, the usage of UCN-01 on 
Chk1 inhibition was not totally successful since its untoward toxicities and 
non-specific inhibition decrease the value as a Chk1 inhibitor (Sausville et al., 
      
 
30 
 
2001). On the other hand, CHIR-124 is a quinolone-based small molecule 
which selectively inhibits Chk1 in vitro (Ni et al., 2006; Tse et al., 2007b). The 
combination of CHIR-124 and topoisomerase poisons was proven to reduce 
proliferation in many p53-mutant cell lines (Tse et al., 2007a; Tse et al., 2007b). 
Furthermore, CHIR-124 was also reported able to induce S and G2/M 
checkpoints and result in cell apoptosis via the synergistic interaction with the 
topoisomerase poisons such as camptothecin or SN-38 in MDA-MD-435 
breast cancer cells (Tse et al., 2007b). Additionally, CHIR-124 was also shown 
to enhance the growth inhibitions and apoptosis of CPT-11 in tumour cells by 
compromising the checkpoint activation (Tse et al., 2007b). However, the 
development of Chk1 inhibitors in clinical cancer therapy is sti ll a challenge as 
it is not easy to confirm that the Chk1 activation has been successfully 
suppressed by the inhibitors. Although the Ser216 phosphorylation of Cdc25C 
in response to DNA damage is widely considered as a marker of Chk1 
activation (Peng et al., 1997; Sanchez et al., 1997), the specific site is also 
constitutively phosphorylated by an unidentified kinase even in undamaged 
cells. This makes it difficult to be a reliable marker of Chk1 inhibition (Kohn et 
al., 2002).  
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The increased expression of -H2AX is considered as another downstream 
marker of Chk1 knockdown in chemotherapy (Abraham, 2004). H2AX was 
revealed to be phosphorylated at serine 139 (-H2AX) in response to Chk1 
inhibition particularly when followed by treated with DNA replication inhibitors 
(Ewald et al., 2007; Syljuasen et al., 2005). Since the increased level of 
-H2AX is recognised as a marker in response to DNA double-strand breaks, it 
is not surprising that loss of Chk1 kinase activity could result in DNA damage 
and further cell apoptosis (Carlessi et al., 2009; Durkin et al., 2006). However, 
instead of playing a direct role in the Chk1 associated signalling transduction 
pathway, -H2AX foci in Chk1-depleted cells were supposed to point out the 
sites of where persistent replication fork defect occurs (Gagou et al., 2010). 
Furthermore, as described previously that Chk1 plays a crucial role which 
ensures genome stability during cell cycle progression, whether secondary 
cancers will appear due to the genetic instability caused by checkpoint 
depletion is not clear. There have been many studies demonstrated that 
inhibition of ATR-Chk1 signalling cascades promotes tumourigenesis in select 
cancer cell lines (Bric et al., 2009; Fang et al., 2004). Therefore, the potential 
side effect that the secondary cancers arise due to Chk1 suppression needs 
more investigation (Tse et al., 2007a).  
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As described previously, tumour cells develop multiple mechanisms and more 
rely on DNA repair and checkpoint systems to evade damage-induced cell 
death. Therefore, it is not surprising that these DNA damage repair and 
signalling to cell cycle checkpoints (or known as DNA damage response, DDR) 
are considered as highly potential candidates for targeted therapy against 
cancer. However, dysfunction of one DNA damage response is sometimes 
functional compensated by another compensatory DDR pathway which 
contributes to drug resistance to DNA-damaging chemotherapy or 
radiotherapy (Curtin, 2012). Therefore, the other very likely reason for the lack 
of clinical efficacy of Chk1 inhibitors may be that the decrease of Chk1 
activation triggers the functional compensation of ATM and ERK1/2 pathways. 
Thus, using a synthetic lethal approach to selectively kill tumour cells which 
are dependent on a compensatory DDR in response to damage-caused stress 
for survival is currently becoming a hot issue. For example, suppression of 
many enzyme activities, non-essential components of cell cycle regulation may 
disturb Chk1 inhibitor–induced ERK1/2 activation and further enhance the 
toxicity of Chk1 inhibitors (Dent et al., 2011). So far, there are still several 
CHK1 inhibitors which are undergoing clinical trials. The potent Chk1/Chk2 
inhibitor AZD7762 is under phase I, dose-escalation study to evaluate the 
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safety, pharmacokinetics (PK) and preliminary efficacy alone or in combination 
with gemcitabine in Japanese patients with advanced solid malignancies (Seto 
et al., 2013). Similarly, other CHK1 inhibitors including PF-477736 (Pfizer) and 
SCH900776 (Schering Plough) are also under Phase I or II clinical evaluation 
in patients (Ashwell et al., 2008; Karp et al., 2012). More Chk1 inhibitors 
applied on clinical trials are listed as a table below: 
Compound Known Targets  Combination Studies  Clinical trials  
UCN-01 PKC family (Mizuno et 
al., 1995) 
Chk1 (Busby et al., 
2000) 
Mytomycin C (Akinaga et 
al., 1993)  
Cisplatin (Bunch and 
Eastman, 1996) 
Topoisomerase I poisons 
(Tse et al., 2007a)  
Gemcitabine (Shi et al., 
2001) 
Phase I/ II 
Gö6976 PKC(Martiny-Baron 
et al., 1993
Chk1 (Jia et al., 2009) 
TrkA/B (Behrens et al., 
1999) 
JAK2 (Grandage et al., 
2006) 
Doxorubicin (Aaltonen et 
al., 2007) 
Cisplatin (Qamar et al., 
2008) 
Radation (Sidi et al., 2008) 
Etoposide (Huigsloot et al., 
2003) 
n/a 
CHIR-124 Chk1 (Tse et al., 2007a; 
Tse et al., 2007b) 
Topoisomerase 1 poisons 
(Tse et al., 2007b) 
Preclinical 
AZD7762 Chk1/2 (Dent et al., 
2011) 
Gemcitabine (Ashwell et 
al., 2008; Seto et al., 2013) 
Phase I 
PF-477736 Chk1 (Dent et al., 2011) Gemcitabine 
(ClinicalTrials.gov) 
Phase I 
SCH900776 Chk1 (Dent et al., 2011) Gemcitabine (Daud et al., 
2010) 
cytosine arabinoside (Karp 
et al., 2012) 
Phase I/II 
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1.2.7 Replication Protein A (RPA) 
When replication stress occurs, RPA (Replication Protein A or also known as 
replication factor A, RFA) quickly coats single-stranded DNA and recruits 
ATR-CHK1 cascades to trigger checkpoint activation. RPA is a stably crucial 
protein complex which consists of three subunits: RPA14, RPA32 and RPA70 
with about 14, 32 and 70kDa respectively (Wold and Kelly, 1988). It has been 
shown to be involved in almost all kinds of cellular DNA metabolism. Activated 
RPA participates in not only DNA replication, recombination or transcription but 
also in many various DNA repair mechanisms such as base excision, 
nucleotide excision, mismatch and DNA double-strand break repair (Wold, 
1997; Zou et al., 2006). The most common feature of RPA is its single-strand 
binding protein (SSB). In contrast to double-stranded DNA or RNA, RPA 
complex has shown a much higher binding affinity to single-stranded DNA 
(Kim et al., 1992). More than 25 years ago, RPA was firstly purified from 
human HeLa cell extracts in which RPA acts as a component of DNA 
replication for simian virus 40 (SV40) in vitro (Wobbe et al., 1987). While the 
genes of RPA32 and 70 subunit are highly conserved in human RPA complex, 
the smallest RPA14 subunit has a much lower conservation level across 
different species (Wold, 1997). It is well accepted that RPA32 and RPA14 act 
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as essential precursors to the proper folding of entire RPA complex whereas 
RPA70 is reported to serve as a DNA binding activity (Henricksen et al., 1994; 
Wold et al., 1989). Since RPA serves as a necessary regulator in DNA 
metabolism, it is not surprising that RPA has primarily been found to localise in 
the nucleus and forms foci during DNA replication (Brush et al., 1995). 
Furthermore, the mRNA expression of RPA was also shown to co-ordinate with 
the cell cycle progression particularly during S phase in both S. cerevisiae and 
C. fasciculatea (Brill and Stillman, 1991; Pasion et al., 1994). RPA32 subunit is 
phophorylated at the conserved cyclin-dependent kinase (CDK) 
phophorylation sites Ser23 and Ser29 by variant protein kinases including 
multiple CDK family and Ser4/8 by DNA-dependent protein kinase (DNA-PK) 
during G1/S phase transition and in M phase in undisturbed cell cycle passage 
(Pan et al., 1994; ZernikKobak et al., 1997). Furthermore, RPA32 can also 
undergo further hyper-phophorylation at Ser4. Ser8 Ser11/12/13, Thr21, Ser23, 
Ser29 and Ser33 following various kinds of DNA damage (Nuss et al., 2005). 
This DNA damage-triggered RPA hyper-phophorylation is considered to be 
activated by phosphatidylinositol 3-kinase-related kinases (PIKKs) family 
including ataxia-telangiectasia mutated (ATM), ataxia- and Rad3-related (ATR) 
and DNA-dependent protein kinase (DNA-PK) (Block et al., 2004). 
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Unfortunately, full details of the role RPA hyper-phosphorylation plays in 
response to DNA damage is still not clearly understood. Although RPA was 
originally considered as a single-stranded DNA binding protein, it is also found 
able to interact with other proteins. For instance, RPA was reported to play a 
necessary role for chromatin association with ATR following DNA strand 
breaks (You et al., 2002). Intriguingly, RPA was also found to act as a sensor 
for ATR recruitment at DNA damage sites and further trigger downstream Chk1 
activation (Ball et al., 2005; Zou and Elledge, 2003). In addition, RPA has been 
reported to be associated with cancers. Up-regulated RPA expression was 
found in several types of tumours including breast and colon cancers and has 
been demonstrated to play a crucial role in cell proliferation during tumour 
growth and progression (Givalos et al., 2007; Tomkiel et al., 2002). L221P 
mutation in the high-affinity DNA binding site of RPA70 subunit has been 
reported to result in defects in checkpoints and DNA repair in yeast (Chen and 
Kolodner, 1999; Chen et al., 1998) and embryonic lethality in mice when 
homozygous (Wang et al., 2005). Even in heterozygous mutant embryonic 
fibroblasts, the mutation in DNA binding subunit of RPA70 results in shortened 
life spans and elevated cancer rates in mouse (Wang et al., 2005). In contrast 
to RPA70, hyper-phosphorylation of RPA32 was shown to facilitate mitotic exit 
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following mitotic DNA damage. When endogenous RPA2 was replaced by a 
mutant subunit, cells were unable to complete mitosis and release early from 
M phase into an abnormal 2N G1 phase (Anantha et al., 2008). Furthermore, 
foci of RPA2 hyper-phosphorylation have also been demonstrated to form and 
dramatically increase in Chk1-depleted colon cancer cells in response to DNA 
replication inhibitor in advance of the induction of apoptosis (Rodriguez et al., 
2008). Taken together, these studies strongly suggest that RPA indeed plays a 
crucial role in DNA damage-induced cell cycle checkpoint mechanism. 
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1.3  Aims and Hypothesis 
During the past decade, the role of Chk1 has been well established and 
reported to participate in tumourigenesis by several studies around the world. 
However, the cell models examined in Chk1 studies were either tumour cell 
lines or normal fibroblasts. The role of Chk1 in normal epithelial cells is still 
poorly understood. Due to the fact that most solid tumours show epithelial 
origins, it is worthwhile to investigate the role of Chk1 in normal epithelial cells. 
siRNA-mediated Chk1 depleted cells have been reported to increase cell 
apoptosis particularly in response to DNA replication defects . This strongly 
suggests that ATR-Chk1 plays a role in protection from cell death under DNA 
replication stress and provides a valuable course for targeted therapy. Here I 
hypothesise that malignant cancer cells rely upon ATR-Chk1 checkpoint for 
survival, however this dependence may not appear in normal epithelial cells. 
The aim of this study is to determine the role of Chk1 especially in normal 
human urothelial cells under DNA replication stress. Through the work to 
define the role of checkpoint signalling transduction cascades in regulating 
DNA replication stress-induced cell cycle aberration in both normal and tumour 
cells will be possible to identify potential mechanisms of cancer transformation 
and able to plan novel managements for bladder cancer therapy.
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Chapter 2 Materials and Methods 
2.1  General laboratory equipments and materials  
2.1.1 General laboratory equipment 
2.1.1.1 Laboratory Equipment 
Equipment Supplier 
7900HT Fast Real-Time PCR System Applied Biosystems 
CellQuest FACS Analysis Software CellQuest 
Class II Biological Safety Cabinet Walker Safety Cabinets 
Ltd 
CO2 Incubator MCO175 Sanyo 
Electronic Pipetting Aid Drummond Scientific Co 
Eppendorf 5415D Centrifuge  Eppenorf 
Eppendorf minispin Centrifuge Eppendorf 
FACsCalibur  Becton Dickinson 
Gel Electrophoresis Unit (WB) Bio-Rad 
Ice Machine Scotsman Ice Machines 
ImageJ Image Processing Software National Institutes 
of Health 
LAS-3000 Chemiluminescence Imaging System Fujifilm 
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Mistral 3000i Centrifuge Sanyo 
MULTISKAN FC Thermo SCIENTIFIC 
P10, P20, P200 and P1000 Pipettes Starpet 
Power Pack 300 Bio-Rad 
Transfer tank Bio-Rad 
PTC 200 DNA engine GRI 
BBA tube Heater Grant Boekel 
RNA quantification (Nano Vue plus) BIOCHROM LTD 
SDS 2.2.1 real-time PCR Analysis Software Applied Biosystems 
SPSS Statistics  IBM Corporation 
The vortex machine  SCIENTIFIC 
INDUSTRIES, INC 
Waterbath Labinco 
 
2.1.1.2 Laboratory Consumables 
Item Supplier 
15ml Centrifuge tubes  Sarstedt 
50ml Centrifuge tubes Corning Inc 
Chapter 2  Materials and Methods  
 
42 
 
6-well plates Cellstar 
10cm Petri dish Greiner bio-one 
384-well PCR plates Life Technologies 
75cm2 Vented culture flasks Nunc 
5ml, 10ml and 25ml Stripettes Corning Inc 
 Sarstedt 
Gilson pipette tips Sarstedt 
Gloves Schottlander 
Syringes BD Biosciences 
Tissue Culture Flask FALCON 
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2.1.2 Laboratory Chemicals 
Item Supplier 
Acrylamide 92.6) 30% Protogel Geneflow #EC-890 
Ammoium Persulphaten VWR Merck #443074F 
B-mercaptoethanol Sigma-Aldrich #M6250 
Bovine Serum Albumin (BSA) Fisher Scientific #BP1600-100 
CHIR-124 SelleckChem #S2683 
DMSO Sigma-Aldrich #101402050 
Ethanol FisherChemical #E/0650DF/17 
Gemcitabine Sigma-Aldrich #G6423 
Gö6976 Sigma-Aldrich #G1171 
Hydrochloric Acid VWR Merck #30024.290 
Hydroxyurea Sigma-Aldrich #H8627 
KU55933 Calbiochem #118500 
KU60019 Selleckchem #S1570 
Methanol FisherChemical #M/4450/17 
MG132 Selleckchem #S2619 
N-Acetylcysteine Sigma-Aldrich #A0737 
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Nocodazole Sigma-Aldrich #M1404 
PhosStop Phosphatase inhibitor Roche #04906837001 
PMSF Sigma-Aldrich #P7626 
Propidium Iodide Sigma-Aldrich #P4170 
SDS BIOLINE #T5-111G 
Soybean trypsin inhibitor Sigma-Aldrich #T6522 
TEMED FisherBioreagent #BP150-20 
Thymidine Sigma-Aldrich #T9250 
Tris-base FisherBioreagent #BP152-1 
Triton X-100 Sigma-Aldrich #X100 
Tween 20 Sigma-Aldrich #P2287 
 
2.1.2.1 Mechanism of action of Drugs 
Thymidine: Increased thymidine inhibits ribonucleotide reductase by elevated 
dTTP or dGTP resulting in a deficiency of dCTP pool and acts as a DNA 
replication inhibitor to synchronize the cells in S phase (Fox et al., 1980). 
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Hydroxyurea: hydroxyurea, also called as hydroxycarbamide decreases the 
production of deoxyribonucleotides (Slater, 1973) by suppressing the 
enzyme activity of ribonucleotide reductase (Platt, 2008). In this study, 
hydroxyurea served as an inducer of DNA replication stress. 
 
Gö6976: 
(12-2(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]py
rrolo[3,4-c]carbazole, M.W. 378.4) Works as a Chk1 inhibitor and inhibits the 
Chk1 Ser296 autophosphorylation (Kohn et al., 2003). 
 
CHIR-124:  
[(S)-3-(1H-benzo[d]imidazol-2-yl)-6-chloro-4-(quinuclidin-3-ylamino)quinolin-2(
1H)-one] is a quinolone-based small molecule which potently and selectively 
inhibits Chk1 in vitro (Ni et al., 2006; Tse et al., 2007b).  
 
KU55933: (2-Morpholin-4-yl-6-thianthren-1-yl-pyran-4-one) an 
ATP-competitive inhibitor of ATM kinase (Hickson et al., 2004). 
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KU60019: KU60019 is an improved inhibitor of ATM kinase from KU55933, 
which is reported 10-fold more effective than previous one in human glioma 
cells (Golding et al., 2009).  
 
Gemcitabine: 
(4-amino-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin-2(1H)-
on 2′,2′-difluoro-2′-deoxycytidine) is a nucleoside analogue which prevents 
cells from making DNA and RNA. During DNA replication, gemcitabine 
replaces the bui lding block, cytidine, resulting in replication termination and 
apoptosis as only one additional nucleoside can be attached to the defect 
nucleoside. Furthermore, gemcitabine also binds to ribonucleotide 
reductase (RNR) and inactivates the enzyme irreversibly, which blocks 
deoxyribonucleotide formation for DNA replication and repair leading to cell 
apoptosis (Cerqueira et al., 2007). Currently, gemcitabine has been approved 
as an anti-tumour drug and applied in clinical cancer therapy to treat various 
solid carcinomas such as bladder, breast, pancreatic and non-small cell lung 
cancer (Toschi et al., 2005). 
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Nocodazole: (Methyl (5-[2-thienylcarbonyl]-1H-benzimidazol-2-yl) serves as a 
mitosis inhibitor which interferes with microtubule polymerization of mitotic 
spindle formation and arrest the cell cycle progression at M phase (Lee et al., 
2004; Sentein, 1977). 
 
N-Acetylcysteine (NAC): NAC is a derivative of cysteine. It is also a 
pharmaceutical drug and nutritional supplement. Acetylcysteine serves as a 
precursor of cysteine which participates in glutathione generation preventing 
damage caused by reactive oxygen species such as free radicals and 
peroxides (Pompella et al., 2003). Hence, N-acetylcysteine is commonly 
considered as a biologic antioxidant reagent. In this study, NAC was used as a 
ROS inhibitor (Ito et al., 2004).   
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2.1.3 Standard Solutions 
i. Purified Water 
Double-distilled water (ddH2O) was generated by Purite Prestige Labwater 
250 purification system. In this thesis, the term “water” was referred to this 
ultra-pure water unless stated separately.  
ii. Phosphate Buffered Saline (PBS) 
PBS was simply prepared by dissolving 10 PBS tablets in 1 litre of water and 
autoclaved. 1 litre PBS buffer contains 8g NaCl, 0.2g KCl, 1.15g Na2HPO4 
and 0.2g KH2PO4. The pH was maintained at 7.4.  
iii. Trypsin-EDTA 
Trypsin is a common reagent which detaches adherent cells from petri-dish, 
cell culture flasks and each other. In this study, trypsin-EDTA is purchased 
from Lonza. 
iv. PBS Tween 20 
PBS Tween20 (PBST) is a solution mixed of Phosphate Buffered Saline 
(PBS), 0.1% BSA and 0.2% Tween 20, used to increase permeability of cell 
membrane. 
v. TBS Tween20 
TBS Tween20 (TBST) is a mixture of Tris-Buffered Saline (a buffer used for 
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maintaining pH) and Tween 20, which used for washing nitrocellulose 
membrane in immunoblotting. 
Chapter 2  Materials and Methods  
 
50 
 
2.1.4 Mammalian Cell Lines and Primary Cells 
In this study, four different cell types were used for research models, see table 
below. 
Cell Tissue Type 
Supplied by 
Reference 
NHU Bladder Normal, Primary Dr. James Catto,  
(Catto et al., 2009) 
hTERT-NHU Bladder Normal, 
hTERT-immortalized 
Prof. Margaret Knowles 
(Catto et al., 2009) 
EJ Bladder Grade IV, Invasive, 
p53 mutated  
ATCC 
TCC-sup Bladder Grade IV, transitional 
cell carcinoma, p53 
mutated 
ATCC 
RT4 Bladder transitional cell 
papilloma, p53 
wild-type 
ATCC 
RT112 Bladder Grade I, p53 
wild-type 
ATCC 
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SW780 Bladder Grade I transitional 
cell carcinoma, p53 
wild-type 
ATCC 
S637 Bladder Grade II, p53 
wild-type 
ATCC 
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2.2  Materials and Methods 
2.2.1 Cell Culture 
2.2.1.1 Cell Culture Mediums 
i. hTERT-NHU (Normal Human Urothelial) and primary NHU cells  
I analyzed both immortalized and primary urothelial cells respectively in this 
work. The former were generated by the transfection of non-immortalized 
urothelial cells (NHU) with human Telomerase Reverse Transcriptase 
(hTERT) (gift of Prof. Margaret Knowles, University of Leeds, UK). NHU cells 
are derived from normal urothelial biopsies (Catto et al., 2009). Both primary 
and NHU-Tert cells were maintained in Keratinocyte Serum-Free Medium 
(KSFMc, purchased from GIBCO) supplemented with EGF, BPE and cholera 
toxin. Purchased EGF and BPE were firstly defrosted in room temperature 
and then added into KSFMc medium directly with 25l cholera toxin.    
ii. Malignant Bladder Tumour Cells 
For comparison, I also analyzed six urothelial carcinoma lines, EJ, TCC-sup, 
RT4, RT112, SW780 and S637 (purchased from the ATCC). With exception 
of RT4 and S637, malignant cells were cultured in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 
1% non-essential amino-acids (NEAA). FCS was supplied by Perbio and 
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stored at -20℃ in 50ml aliquots. Before being added to the DMEM medium, 
FCS was dialyzed in advance to remove deoxynucleosides that may affect 
the response to subsequent drug treatments. While RT4 was grown in 
McCoy culture medium supplemented with 10% fetal calf serum (FCS), S637 
was cultured with RPMI medium plus 10% FCS. The preparation of FCS was 
the same as with other tumour cell lines which were described previously.  
 
2.2.1.2 Cell Culture Procedure 
i. Malignant Bladder Tumour Cells 
Tumour cells were maintained with DMEM in a 37℃ incubator with 5% 
CO2 levels. Once these cells were observed to be 90 to 100% confluent or 
the colour of medium was changed due to pH alteration in response to cell 
secretions or cell death, they were split at a 1:8 ratio. Culture medium was 
firstly removed. In order to avoid any possible interference of divalent 
cations or proteins, cells were then washed with PBS and trypsinized with 
1ml trypsin-EDTA in 37℃ for about 5 minutes to be detached. Fully 
detached cells were harvested with fresh DMEM medium and cultured in 
new petri-dishes in the incubator. 
ii. Normal Human Urothelial (NHU) cells  
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Both immortalized hTERT-NHU and primary NHU cells were maintained 
with KSFMc medium in 37℃ supplied with 5% CO2 like tumour cells 
described previously. The procedures of cell passage were generally the 
same as tumour cells that mentioned previously except without PBS 
washing. Notably, the medium used for detached cells collection must be 
augmented with trypsin inhibitor (50l in 5ml medium). 
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2.2.2 Western Blot 
In this study, protein activation and total protein levels were analyzed by 
western blot (or called immunoblot). It is a common technique to detect protein 
levels by different molecular weights of each protein in total protein lysate and 
widely used in molecular biology, biochemistry or immunology. Since antibody 
is able to recognize its specific protein antigen, proteins are firstly separated by 
polyacrylamide gel electrophoresis (PAGE) and probed by antibodies. 
According to the intensity and the position of blots, the signal of protein 
expression in cells is capable of analysis. 
 
2.2.2.1 Drug Treatment and Protein Extraction 
5×106 cells were seeded into 6-well culture dish for 24hr for cell attachment. 
On the day for drug treatment, cells were refreshed with 37℃ pre-warmed 
fresh medium and treated with drugs (eq. thymidine, hydroxyurea, Chk1 
inhibitor or ATM inhibitor, etc.) for appropriate time points. Afterwards, medium 
was removed and cells were carefully rinsed with PBS for 4 times. 40l lysis 
buffer which contains 25mM Tris-HCl (pH 8.0), 150mM NaCl, 0.5% sodium 
deoxycholate, 1% NP-40, 0.1% SDS, 1M PMSF (phenylmethylsulphonyl 
fluoride), Protease inhibitor mix, Phosphatase inhibitor mix and 
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ß-mercaptoethanol were used to lyse cells. Cell lysates were collected into 
1.5ml microtube and cooled down on ice for 15minutes with vo rtex in every 5 
minutes followed by a 5 minutes max-speed centrifugation. Supernatant 
suspension (total proteins) was then transferred to a new 1.5ml eppendorf and 
kept in -80℃ freezer for later protein quantification.  
 
2.2.2.2 Protein Quantification 
A protein standard curve and protein samples were prepared as the table 
below. 
The absorbance of each solution was measured by photometer at wavelength 
OD595nm and resulting in a standard curve (R
2 > 0.98). According to this, protein 
concentration can easily be calculated by inner interpolation against the 
standard curve. 
 
 
 
BSA 1 mg/mL RIPA buffer Sample H2O Bradford reagent
Blank - -
s
ta
n
d
a
rt
 c
u
rv
e 2.5 -
5 -
10 -
20 -
40 -
80 -
Sample - -
2 L 798 L 200 L
2.5 L 2 L 795 L 200 L
5 L 2 L 793 L 200 L
10 L 2 L 788 L 200 L
20 L 2 L 778 L 200 L
40 L 2 L 758 L 200 L
80 L 2 L 718 L 200 L
2 L 798 L 200 L
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2.2.2.3 Polyacryamide Gel Electrophoresis 
Polyacryamide gels were prepared as the table below. 
While stacking gel is made to stack all the samples of different lanes at the 
same starting line due to its low pH (6.8) and percentage, resolving gel 
separates varied proteins by their sizes. The polyacryamide percentage of the 
gel is directly related to how difficult it is for proteins to pass through the gel 
during the process of electrophoresis. Within the higher percentage of gel, the 
lower mobility is shown of proteins. Hence, different proteins with varied 
molecular weights were fractionated with different concentration of 
polyacryamide gels. For instance, proteins with large molecular weight (> 
200KDa) such as ATM and DNAPK are recommended to be fractionated in 6% 
gels. Prepared gel solution was poured between two glass plates and set on 
Bio-Rad electrophoresis system. Protein samples were mixed with 2X protein 
SEPARATING GEL 15.00% 12.00% 10.00% 8.00% 6.00%
30% polyacrylamide 10 mL 8 mL 6.7 mL 5.3 mL 4 mL
1 M Tris pH 8.8 7.5 mL 7.5 mL 7.5 mL 7.5 mL 7.5 mL
10% SDS 0.2 mL 0.2 mL 0.2 mL 0.2 mL 0.2 mL
H2O 2 mL 4 mL 5.3 mL 6.7 mL 8 mL
10% APS 0.250 mL 0.250 mL 0.250 mL 0.250 mL 0.250 mL
TEMED 0.025 mL 0.025 mL 0.025 mL 0.025 mL 0.025 mL
20 mL 20 mL 20 mL 20 mL 20 mL
STACKING GEL 5.00%
30% polyacrylamide 1.7 mL
1 M Tris pH 6.8 1.25 mL
10% SDS 0.1 mL
H2O 6.8 mL
10% APS 0.125 mL
TEMED 0.0125 mL
10 mL
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loading buffer at 1:1 ratio and heated at more than 95℃ for 5 minutes to 
denature protein’s higher structure folding and loaded into settled gels. The 
system is run at constant 35mA/gel for 2hr with TGS running buffer.  
 
2.2.2.4 Protein Transfer 
In this study, nitro cellulose membrane was used as a carrier for protein 
transfer from the gels. Protein will be bound to this specific membrane by 
hydrophobic interactions, as well as charged interactions as its denatured 
polypeptide form and keeps the bioactivity unchanged. Once running of 
electrophoresis was finished, the gel could be removed from the apparatus 
and prepared for later protein transfer. The stacking gel was discarded. 
Membrane, resolving gels and blotting papers were incubated with transfer 
buffer (diluted from 100ml 10X transfer buffer with 200ml methanol and 700ml 
water) for half an hour on shaker. Afterwards, the sandwich cascade was set 
as blotting paper → gel → membrane → blotting paper from electric current 
negative to positive and put into transfer tank full with transfer buffer at 200mA 
for 90 minutes. Transferred membrane was then blocked with TBST containing 
5% skim milk for at least 1hr under room temperature on shaker. 
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2.2.2.5 Probing for Proteins of Interest 
Following protein transfer, blocked membrane was then incubated at 4℃ 
overnight with specific first antibodies. These antibodies were diluted with 5% 
skim milk which is the same as blocking at appropriate concentration. The 
rabbit monoclonal antibody against -actin was used as an internal control.  
 
First antibodies in this study are listed as a table below: 
Antibody Dilution Source 
p-Chk1 S296 1:500 #2349S, Cellsignaling 
p-Chk1 S317 1:500 #2344S, Cellsignaling 
p-Chk1 S345 1:500 #2348S, Cellsignaling 
Chk1 1:1000 #2360, Cellsignaling 
p-ATM S1981 1:3000 #2152-1, EPITMIC 
ATM 1:1000 #K0909, SantaCruz 
p-Chk2 T68 1:500 #2661, Cellsignaling 
Chk2 1:1000 Ab8108, abCam 
P53 1:1000 #9282S, Cellsignaling 
p-P53 S15 1:500 #9284S, Cellsignaling 
RPA 1:1000 NA19L, Calbiochem 
p-RPA2 S33 1:1000 A300-246A, BETHYL 
p-RPA2 S4/8 1:1000 A300-245A, BETHYL  
-H2AX 1:500 #2577, Cellsignaling 
Active-caspase3 1:1000 Ab2302, abcam 
Cyclin D1 1:1000 #2926, Cellsignaling 
Cyclin E 1:1000 #4129S, Cellsignaling 
CDK6 1:1000 #3136S, Cellsignaling 
CDK4 1:1000 sc-260, Santa Cruz  
P16 1:1000 Ab54210, abcam 
P19 1:1000 sc-56334, Santa Cruz 
P21 1:1000 #2947S, Cellsignaling 
p-RB S780 1:1000 #9307S, Cellsignaling 
LC3B 1:1000 #2775S, Cellsignaling 
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c-Myc 1:1000 #9402S, Cellsignaling 
-actin 1:3000 A5060, Sigma 
 
After this the membrane was washed four times, 5 minutes each with TBST 
and incubated with HRP (horseradish peroxidase)-conjugated secondary 
antibodies. The enzyme HRP was firstly found in horseradish and widely used 
in research as it is able to amplify a weak signal and increase the sensitivity of 
detection of the specific target while reacted with some certain substrates. 
Here I performed the HRP-conjugated immunoblotting with Enhanced 
chemiluminescence (ECL) system. During the process of the enzyme 
catalysed the oxidation of substrates, the reaction emitted low intensity of light. 
However, the light will be increased up to 1000-fold in the presence of some 
specific molecules such as p-iodophenol, a modified phenol. (Kapeluich et al., 
1997; Kim et al., 1991). In this study, the emitted light was detected and 
analysed by LAS-3000 programme. 
 
The table of secondary antibodies 
Antibody Dilution Source 
Anti-mouse IgG 1:1000 #7076S, Cellsignaling 
Anti-rabbit IgG 1:1000 #7074S, Cellsignaling 
 
Chapter 2  Materials and Methods  
 
61 
 
2.2.3 Flow Cytometry analysis 
Flow Cytometry, or called FACS (Fluorescence Activated Cell Sorting) is a 
biological technique based on laser which beams passing fluid stream 
resulting the specific light scattering and fluorescence of cells. FACS is widely 
applied in various fields of biological research such as cell counting, cell 
sorting and biomarker detection by analyzing the pre-labelled fluorescence 
signal on each single cell or bio-molecule in a stream of fluid passing through 
the electronic detection apparatus. In this study, FACS was employed to 
examine cell cycle alteration, cell death and status of DNA replication in 
response to some specific treatments. 
 
2.2.3.1 Sample Preparation 
In total, 5×105 cells were seeded into 6-well culture dish for 24 hours to allow 
attachment. After treatment, medium containing floating cells was firstly 
collected into 15ml tube. Cells were then washed with 1ml PBS and trypsinized 
with 1ml trypsin-EDTA in 37℃ for about 5 minutes to be detached. Fully 
detached cells were harvested with those pre-collected medium and 
centrifuged at 1000rpm (here equal to 179g) for 3 minutes to remove 
suspension. Cell pellet was then washed with 1ml PBS at 1000rpm for 3 
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minutes again and fixed with 70% ethanol to increase the permeability for later 
propidium iodide staining. Fixed cells were finally stored in -20℃ freezer and 
ready for later experiments. 
 
2.2.3.2 Cell Cycle analysis (PI, Propidium iodide) 
On the day of FACS analysis, ethanol-fixed samples were centrifuged at 
1000rpm (here equal to 179g) for 3minutes and washed 2 times with 2ml PBS 
to remove ethanol. Afterwards, RNaseA was mixed gently with samples to 
eliminate the possible interferences of RNA and stained with Propidium iodide 
(PI) for at least 30 minutes. PI is a common intercalating agent and a 
fluorescent molecule which is capable of inserting into DNA double strands. 
Once PI is inserted into nucleic acid strands, its red fluorescence is enhanced 
20- to 30-fold to enable detection. Since the binding of PI between nucleic 
acids reflects the amount of DNA directly and due to the fact that DNA amount 
changes during cell cycle progression, Propidium iodide is commonly used 
for detecting DNA content in cell cycle analysis. Here I used PI staining with 
FACS analysis to examine the population for cell death as small DNA 
fragments occurs during the late stage of apoptosis and cell cycle alteration in 
response to our specific treatments. 
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2.2.3.3 Detection of BrdU incorporation in S-phase cells 
Fixed cells were washed twice with 2ml PBS and pelleted at 1300rpm (here 
equal to 179Xg) for 3 minutes and then re-suspended in 1ml 2M HCl to 
denature DNA double-strands and to allow detection of incorporated BrdU. 
Acid was added drop by drop to the cell pellet with simultaneously vortexing. 
After 30 minutes room temperature incubation, samples were spun at 1300rpm 
for 3 minutes and washed twice with 2ml PBS plus once with PBST 
(PBS+0.1%BSA+0.2% Tween20) to remove acid and make cells permeable. 
In 100l PBST, I added 2l mouse anti-BrdU (DakoCytomation, M0744) as 
1/50 dilution for 20 minutes incubation in dark. After that, cells were spin-down, 
washed with 2ml PBST again and incubated with rabbit anti-mouse FITC 
conjugated antibody (DakoCytomation, M0313) as 1/10 dilution in dark for 20 
minutes. Finally, secondary antibody bound cells were spun down and washed 
with 2ml PBS for staining with about 400l PI solution and RNaseA as 
described in previous section. 
 
Both PI stained and BrdU incorporated cells were analysed with CellQuest 
programme (BD Biosciences). 
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2.2.4 Real-Time PCR 
PCR (Polymerase Chain Reaction) is also a widely used technique to amplify a 
single copy of a gene or a particular DNA sequence to thousands or millions of 
copies. This reaction relies on semi-conservative model of DNA replication of 
ssDNA and various DNA states under different temperatures. In general, while 
DNA double strands denature and anneal again at 95℃ and around 60℃ 
respectively, the thermal-stable DNA polymerase works at about 72℃. Hence, 
during PCR progresses, DNA samples undergo successive cycles of heating 
and cooling to let DNA double strains repeated melting and 
enzymatic replication. However, products of traditional PCR can only be 
analysed by gel electrophoresis after the full cycles are completed. It is difficult 
to make a comparison between the level of samples of interest and control 
gene once the PCR reaction reaches plateau period. On the other hand, 
real-time PCR, or called quantitative PCR (qPCR) is based on the general 
principle of standard PCR and able to record DNA replication products in the 
end of every cycle in “real-time” by detecting non-specific fluorescent dyes or 
pre-labelled specific probes. This allows more accurate and stable 
quantification of the increased DNA fragments. 
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2.2.4.1 RNA Extraction and Quantification 
In this study, RNA extraction was performed by GenElute Mammalian Total 
RNA Miniprep Kit. Treated cells were firstly washed and harvested into 15mL 
tubes as the standard procedure described previously. Centrifuged pelleted 
cells were then lysed by the Lysis Solution/2-ME Mixture and thoroughly 
vortexed until all clumps disappeared. To remove cellular debris and 
fragmented DNA, cell lysate was put into a GenElute Filtration Column and 
centrifuged at max speed for 2 minutes. After that, an equal volume of 70% 
ethanol solution was added and mixed thoroughly to the filtered lysate. 
Maximum 700 L of the lysate/ethanol mixture was put into a GenElute 
Binding Column for a 15-second maximum speed centrifugation. The binding 
column was then returned to the collection tube and any remaining 
lysate/ethanol mixture was applied to the column. The column was washed 
with 500 L Wash Solution 1 by a 15-seconds maximum speed centrifugation. 
The binding column was then transferred into a fresh 2 ml collection tube and 
washed two times with 500 L ethanol-diluted Wash Solution 2 with another 
15-second maximum speed centrifugation. The binding column must be free of 
ethanol before RNA elution. Thus, in order to further dry the column, it was 
centrifuged for an additional 1 minute at maximum speed. Finally, the binding 
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column was transferred into another fresh 2 ml collection tube. 50 L of the 
Elution Solution was added into the column and centrifuged at maximum 
speed for 1 minute. Purified RNA was now in the flow-through elute and ready 
for removal of DNA or storage at a -70℃ freezer. 
 
2.2.4.2 Removal of DNA from RNA Extraction Samples 
Total RNA samples were treated with DNase I to remove all possible DNA 
contaminations. Samples were firstly prepared as below: 
 Total RNA (10-50g): 50l 
 10X incubation buffer: 6l 
 DNaseI, RNase free: 1l 
 DEPC water: 3l 
Then prepared samples were incubated at 37℃ for 20 minutes. In order to 
remove all DNase and salt, samples were passed again through the column as 
described previously. Purified DNA-free RNA samples were quantified by the 
measurement of A260/A280 absorbance. 
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2.2.4.3 Reverse Transcription-PCR (RT-PCR) 
Reverse transcription-PCR (RT-PCR) is a PCR-based biological technique that 
converts an RNA chain to a complementary DNA sequence. This 
complementary DNA chain then further serves as a template for later DNA 
replication. For first strand cDNA synthesis, primed RNA was prepared as 2g 
total RNA+1l (0.5g) oligo dT 18+DEPC water till total 10l for 5 minutes 70℃ 
incubation. Meanwhile, the reaction mix was prepared as described below: 
 4l 5X RT buffer 
 1l RNase inhibitor 
 1l 10mM dNTP mix 
 0.5l (200U/l) Reverse transcriptase BIOLINE 
 Till 10l diethylpyrocarbonate (DEPC) water 
10l reaction mix was added into incubated primed RNA for total 20l volume 
and incubated at 42℃ for 1 hour. Finally, the reaction was stopped at 70℃ for 
10 minutes and stored at -80℃.  
 
2.2.4.4 qPCR 
In this study, qPCR reaction was performed by Thermo Scientific Solaris qPCR 
Assay Kit. cDNA pool prepared from the previous reaction was diluted by 
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adding 30-40l DEPC water. 1l diluted cDNA pool was enough for each 
qPCR reaction. 
 
qPCR reaction 
Master Mix: 
2X SensiMix SYBR:  5l 
10M forward primer: 0.25l (250nM final) 
10M reverse primer: 0.25l (250nM final) 
Water:              up to 4.5l 
 
Template: 1l diluted cDNA 
Final volume per reaction: 10l 
 
qPCR Thermal Cycling Programme 
 Temperature Time Number of Cycles 
Enzyme activation 95℃ 15 minutes 1 cycle 
Denaturation 95℃ 15 seconds 40 cycles 
Annealing/Extention 60℃ 60 seconds 
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CHEK1 Forward primer: ACTTCCGGCTTTCTAAGGGTGA 
       Reverse primer: GCAGGAAGCCAAATCTTCTG 
       Probe:ATTGATATTGTGAGCAGCC 
 
ACTB Forward primer: TGGAGAAAATCTGGCACCAC 
     Reverse primer: GGTCTCAAACATGATCTGG 
     Probe: ACCGCGAGAAGATGACC 
 
Data were analysed by SDS 2.2.1 programme.   
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2.2.5 Statistics 
SPSS 10.0 (one way ANOVA followed by Post-hoc analysis with Bonferroni 
correction; SPSS Inc., Chicago, IL, USA) was applied for statistical analysis in 
this study. All the experiment results in this thesis were repeated at least three 
times. Values are means ± S.E. from at least 3 different samples. P＜0.05 was 
recognised the statistical significance between categories.
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Chapter 3 The response of normal urothelial 
cells to CHK1 inhibitors. 
3.1  Introduction 
It has been demonstrated that loss of cell cycle control enhances the 
accumulation of genetic alterations leading to transformation of normal cells to 
tumour cells, which eventually generates and develops to invasive, metastatic 
cancers. In response to DNA damage or replication stress, checkpoints are 
triggered to arrest cell cycle progression, which provides time for DNA repair. 
Activated checkpoints not only induce cell cycle arrest or cell death in 
response to some types of DNA damage (Nakano and Vousden, 2001; Yu et 
al., 2001) but also shown to protect tumour cells from apoptosis (Meuth, 2010; 
Rodriguez and Meuth, 2006; Sidi et al., 2008). In eukaryotic cells there are two 
highly conserved signalling cascades: two members of the phosphatidylinositol 
3-kinase-like family of kinases, Ataxia telangiectasia mutated (ATM) and ATM 
and Rad3 related (ATR) (Ciccia and Elledge, 2010) participate in these 
systems. Under DNA damage or replication stress, these activated kinases 
phosphorylate a number of downstream proteins to protect DNA integrity, 
including two key protein kinases, checkpoint kinase 1 (CHK1) and checkpoint 
kinase 2 (CHK2) (Bartek and Lukas, 2003). Both CHK1/CHK2 are 
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serine/threonine protein kinases that participate in checkpoint signalling 
cascades, however they have been demonstrated to be activated by many 
different upstream regulators (Bartek and Lukas, 2003; Stracker et al., 2009). 
In general, the ATM-CHK2 signal transduction pathway responds to DNA 
double strand breaks (DSBs) or ends, however the ATR-CHK1 pathway is 
mainly activated in response to DNA replication stress and the accumulation of 
single stranded DNA at stalled replication forks. CHK1 is an unstable protein. 
Its expression is mainly restricted to S and G2 phases (Kaneko et al., 1999). In 
contrast CHK2 is stable and expressed throughout the cell cycle. This feature 
honestly reflects the role of the ATM-CHK2 signalling cascade that is 
responsible for repairing DNA damages which may occur throughout the cell 
cycle (Lukas et al., 2001). 
 
Recently the interest in the use of CHK1 inhibitors in cancer therapy has grown 
dramatically (Bennett et al., 2012; Blackwood et al., 2013; Carrassa and 
Damia, 2011; Cole et al., 2011). CHK1 kinase has been reported not only to 
regulate cell cycle progression from S to M phase following disruption of DNA 
replication or some types of DNA lesion but also play a role in S phase 
procession even in undisturbed cells (Petermann and Helleday, 2010; 
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Petermann et al., 2006). CHK1 plays a vital role in mammalian development 
and viability. Once CHK1 is knocked out, it causes embryonic lethality in mice 
(Liu et al., 2000; Takai et al., 2000). Cells cultured from early embryos of such 
strains have exhibited failure to survive and shown extensive cell apoptosis 
(Takai et al., 2000). Although CHK1 knockdown or depletion is not invariably 
lethal, delayed cell growth with a particularly slower progression through 
S-phase and increased levels of spontaneous apoptosis have been shown in 
many cell types depleted of CHK1 (Petermann et al., 2006; Zachos et al., 
2003). However when DNA replication is disrupted, siRNA-mediated CHK1 
depletion or small molecule inhibition of CHK1 have been demonstrated to 
trigger cell death in many cell types (Myers et al., 2009; Rodriguez and Meuth, 
2006). These findings indicate that CHK1 plays a role in protecting cells from 
apoptosis caused by DNA replication stress. However, the principal cell 
models uti lized for CHK1 studies have been either cancer cell lines or 
immortalized fibroblasts. Due to the fact that most tumours have an epithelial 
origin, it is worthwhile to understand the role of these pathways in normal 
epithelial cells for more effectively target therapy developments to beat 
developing tumour cells.  
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3.2  Aims and Hypothesis 
While DNA damage response pathways are well characterized in cancer cells, 
much less is known about their status in normal cells. These pathways protect 
tumour cells from endogenous DNA damage and oncogene-induced 
replication stress and consequently present potential therapeutic targets. 
Given that normal cells may be less prone to such stresses, the hypothesis of 
this project was that the DNA damage response may be very different in 
normal human epithelial cells. To test this hypothesis, the responses of both 
primary and hTERT-immortalized normal human urothelial (NHU) cells to DNA 
replication inhibitors were characterised. In this work, the effects of replication 
inhibitors on cell cycle progression, checkpoint induction, and apoptosis were 
analysed by FACS, Western blotting and immunofluorescence in these cells. 
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3.3  Results 
3.3.1 CHK1 inhibition slows S-phase progression in response to 
DNA replication stress in both primary and hTERT-NHU cells but 
does not trigger apoptosis. 
To determine the response of non-malignant epithelial cells to DNA replication 
stress, hTERT-NHU cells were treated with thymidine for 24 or 48hr in the 
presence or absence of the CHK1 inhibitor Gö6976. Cells were harvested and 
analysed for DNA content by flow cytometry. Unlike the malignant tumour cells 
which were previously reported in 2010 (Gagou et al., 2010), these 
non-malignant urothelial cells showed totally different response. Cells treated 
with the CHK1 inhibitor alone for 24 or 48hr did not show any significant 
alteration in cell cycle distribution compared with untreated control (Fig. 3.1). 
Cultures treated with thymidine showed a significant accumulation of cells in 
S-phase, which stand for a slow progression through S-phase. Following 24hr 
treatment with a combination of thymidine and Gö6976, cells still arrested in 
S-phase, which is similar to those treated with thymidine alone (Fig. 3.1A). 
However when exposure time was extended to 48hr, hTERT-NHU cells under 
the combination treatment failed to progress further through S-phase while the 
cells treated with thymidine alone were able to progress slowly through S and 
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accumulated in G2 (Fig. 3.1B). Notably, only few hTERT-NHU cells treated with 
the combination showed a sub-G1 population which is characterised as 
apoptotic cells. 
 
 
FIGURE3. 1. CHK1 inhibitor slows S-phase progression in hTERT-NHU 
cells in response to replication stress but does not trigger death.  
hTERT-NHU cells were pre-treated with 1M CHK1 inhibitor (Gö6976) for 2h 
and then incubated with or without 1mM thymidine for A) 24h and B) 48h 
before harvest and analysis for cell cycle distribution by flow cytometry. Values 
presented represent the mean of at least three independent experiments 
+standard deviation. *P<0.05 compared with untreated control cells. SubG1 
population of EJ cells serves as positive control (presented as Fig. 4.1A, 
Chapter 4) 
A 
B 
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To further examine the effect of Chk1 inhibition in normal urothelial cells upon 
DNA replication stress, a second Chk1 inhibitor, CHIR-124 was also tested in 
hTERT-NHU cells in response to 24hr thymidine treatment. In contrast to 
Gö6976, Chir124 arrested hTERT-NHU cells in late S/G2/M but still failed to 
trigger cell death (Fig. 3.1C). 
 
FIGURE3.1C. Other CHK1 inhibitor also fail to induce apoptosis in 
hTERT-NHU cells.  Representative profiles of hTERT-NHU cells treated with 
the CHK1 inhibitor Chir124 (right panels) in the presence or absence of 
thymidine (lower panels). 
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Furthermore, treated primary human urothelial cells were similarly treated to 
see their responses to Chk1 inhibitor and/or DNA replication stress. Like the 
hTERT-immortalized cells, these cells accumulated in S- and G2/M phase in 
response to thymidine or thymidine and Gö6976, but no significant sub-G1 
population was detected (Fig. 3.1D). 
 
 
FIGURE 3.1D. CHK1 inhibitor slows S-phase progression in primary NHU 
cells in response to replication stress but does not trigger death.  
Primary NHU cells were pre-treated with 1M CHK1 inhibitor (Gö6976) for 2h 
and then incubated with or without 1mM thymidine for 24 before harvest and 
analysis for cell cycle distribution by flow cytometry. Values presented 
represent the mean of at least three independent experiments +standard 
deviation. *P<0.05 compared with untreated control cells. 
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Additionally, hTERT-NHU cells treated with another replication inhibitor, 
hydroxyurea in the presence or absence of the Gö6976 were also analysed. 
Like the treatment of thymidine, hydroxyurea only triggered S-phase 
accumulation without significant induction of sub-G1 population (Fig. 3.1E). 
 
 
FIGURE 3.1E. Other replication inhibitors also fail to induce apoptosis in 
hTERT-NHU cells.  hTERT-NHU cells were pre-treated with 1 mM CHK1 
inhibitor (Gö6976, 1M, right panels) for 2 hr before addition of 0.5 or 1 mM 
HU for 24h (lower panels). Cells were then harvested and analysed for DNA 
content. Values presented represent the mean of at least three independent 
experiments +standard deviation. * P<0.05 compared with untreated negative 
control (NC) cells. 
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3.3.2 The role of Chk1 in hTERT-NHU cells in response to clinical 
anti-cancer drug gemcitabine. 
The effect of Gö6976 on the response to the deoxycytidine analog gemcitabine 
which is widely used in the treatment of advanced bladder cancer was further 
examined. Cells were treated with 12.5 nM gemcitabine in the presence or 
absence of a 2hr pre-incubation with Gö6976. Consistent with the response 
triggered by thymidine, no significant cell death was induced by a 24h 
co-treatment with gemcitabine and Gö6976 in hTERT-NHU cells (Fig. 3.2). 
 
FIGURE3. 2A. Gemcitabine induces no apoptosis in hTERT-NHU cells 
when CHK1 is inhibited.  hTERT-NHU cells were pre-treated with  
Gö6976 for 2 h and then incubated with or without 12.5nM Gemcitabine for 
24h before harvest and analysis for cell cycle distribution by flow cytometry. 
Values presented represent the mean of at least three independent 
experiments +standard deviation. * P<0.05 compared with untreated negative 
control (NC) cells. Note: The induction of sub-G1 populations in EJ cells serves 
as a positive control (presented as Fig. 4.3) 
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Taken together, these results show that the combination of DNA replication 
stress agent and small molecule-caused CHK1 inhibition is unable to trigger 
cell death in both primary and hTERT-immortalized NHU cells.  
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3.3.3 Western blot analysis of DNA damage response proteins in 
Chk1 inhibited hTERT-NHU cells treated with thymidine. 
To determine how regulatory CHK1 participates in checkpoint mechanism and 
cell cycle regulation in hTERT-NHU cells exposed to replication inhibitors, 
cultures were treated with thymidine following the presence or absence of 
Gö6976 treatment for different time points and harvested for Western blot 
analysis as well. CHK1 autophosphorylation at Ser296 readily appeared in 
both untreated control and thymidine treated hTERT-NHU cells. This event 
was completely suppressed by Gö6976, demonstrating the effectiveness of 
the kinase inhibition. In contrast, the crucial Ser345 phosphorylation of CHK1 
could not be detected even after a 24hr thymidine treatment while CHK1 
pSer317 phosphorylation was transiently observed after an 8hr treatment (Fig. 
3.3A). 
 
In contrast, although ATM showed an early response (presented in Chapter 5) 
Chk2 seems only poorly affected in this signalling transduction cascade as 
only little phosphorylated and total protein level of Chk2 showed apparent 
changes in hTERT-NHU cells in response to Gö6976-induced CHK1 inhibition 
(Fig. 3.3A). 
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FIGURE3. 3A. Western blot analysis of Chk1/2 phosphorylation in 
hTERT-NHU cells treated with thymidine in the presence or absence of 
CHK1 inhibitor. hTERT-NHU cells were exposed to 1mM thymidine for 0-24h 
in the presence or absence of 1M Gö6976 before harvest and preparation of 
cell free extracts. Cells treated with Gö6976 were pre-incubated with the 
inhibitor for 2h before addition of thymidine, those treated with the CHK1 
inhibitor alone (0h thymidine) were exposed for 26h. Western blots prepared 
from these extracts were analysed for the indicated phosphorylated Chkl and 
Chk2 proteins. -actin levels are presented as loading controls. Note: p-Chk2 
(Thr68) expression was weak, thus the exposure time for image capture 
system was more than 2hr; Expression of p-Chk1 Ser345 in EJ cells serves as 
a positive control (presented as Fig. 4.2A, Chapter 4) 
 
Total levels of other damage signaling response associated proteins in 
hTERT-NHU cells were also examined in response to the treatment. p53 was 
stabilized and phosphorylated after 12hr treatment while the total protein level 
of CHK1 strikingly decreased in cells following CHK1 inhibitor treated in either 
presence or absence of thymidine (Fig. 3.3B). Notably, while pSer139 H2AX 
Chapter 3  The Response of Normal Urothelial Cells to CHK1 Inhibitors  
 
86 
 
(-H2AX) was only weakly detected in hTERT-NHU cells treated with thymidine 
alone, both RPA and H2AX phosphorylation were apparently detected at later 
times in cells following the combined treatment of Gö6976 and thymidine (Fig. 
3.3B). 
 
 
FIGURE 3.3B. Western blot analysis of DNA damage response proteins in 
hTERT-NHU cells treated with thymidine in the presence or absence of 
CHK1 inhibitor.  hTERT-NHU cells were exposed to 1mM thymidine for 
0-24h in the presence or absence of 1M Gö6976 before harvest and 
preparation of cell free extracts. Cells treated with Gö6976 were pre -incubated 
with the inhibitor for 2h before addition of thymidine, those treated with the 
CHK1 inhibitor alone (0h thymidine) were exposed for 24h. Western blots 
prepared from these extracts were analysed for the indicated damage 
response proteins. -actin levels are presented as loading controls. 
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3.3.4 RPA and -H2AX foci are activated in hTERT-NHU in 
response to the combination of CHK1 and replication inhibitors. 
The foci formation by RPA and -H2AX are further confirmed by 
immunofluorescence. Combined treatment of CHK1 inhibitor and thymidine 
showed enhanced RPA and -H2AX foci formation in hTERT-NHU cells 
relative to cells treated with thymidine or Gö6976 alone (Fig. 3.4). However, 
compared with the previous report based on tumour cells such as HCT116, the 
-H2AX foci were more distinct and localized in hTERT-NHU cells and the 
pan-nuclear -H2AX staining found in tumour cells caused by these conditions 
(Gagou et al., 2010) was not evident in hTERT-NHU cells either. 
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FIGURE3. 4. Immunofluorescence analysis of RPA and -H2AX foci in 
hTERT-NHU cells treated with thymidine in the presence or absence of 
CHK1 inhibitor.  Representative images from immunofluorescence analysis 
of RPA and -H2AX foci in hTERT-NHU cells treated with 1mM thymidine and 
1M Gö6976. Due to the multiple phosphorylation sites of RPA, the antibody 
against total RPA was used in these experiments. Bar graphs present the 
mean of at least three independent experiments +standard deviation of 
hTERT-NHU cells treated with 1mM thymidine for 24h with or without Gö6976 
(1M). *P<0.05 compared with untreated control cells. 
 
  
RPA foci -H2AX foci 
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3.3.5 RPA is only partially phosphorylated in hTERT-NHU in 
response to DNA replication inhibition.  
To further confirm whether replication stress-induced RPA 
hyperphosphorylation in CHK1 inhibited hTERT-NHU cells is associated with 
ATR-Chk1 pathway, different phosphorylation sites of RPA was examined by 
immunoblotting. Interestingly, RPA was only phosphorylated at Ser4/Ser8 but 
no Ser33 phosphorylation was found in these cells (Fig. 3.5). Notably, 
compared with chemical inhibition of the kinase inhibitor, HCT116 was 
considered as a positive control with its siRNA-caused cellular protein 
depletion. 
 
FIGURE3. 5. Western blot analysis of phosphorylated forms of RPA2 in 
extracts prepared from hTERT-NHU cells.  hTERT-NHU cells treated with 
1mM thymidine for 24h with or without Gö6976 (1M). HCT116 cells treated 
with CHK1 siRNA and thymidine were generously gifted by Dr. Zuazua-Villar 
and presented as a positive control for full hyperphosphorylation of RPA2 
(Gagou et al., 2010; Rodriguez et al., 2008). 
 
Since it has been shown that Ser33 is phosphorylated by ATR under such 
conditions (Anantha et al., 2007; Vassin et al., 2009), the absence of Ser33 
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phosphorylation further suggests that ATR-CHK1 signalling may not be fully 
activated in response to CHK1 and replication inhibitors in the hTERT-NHU 
cells. This suggestion was further confirmed by the evidence of reduced 
RAD51 foci in response to DNA replication stress. CHK1-dependent RAD51 
has been known to form foci at stalled forks during DNA replication arrest 
(Sorensen et al., 2005). Compared with HCT116 colon cancer cells which are 
known to form RAD51 foci in response to replication stress, only 25% of 
hTERT-NHU cells showed >10 RAD51 foci following thymidine treatment 
whereas more than 90% of HCT116 cells presented a similar response (Fig. 
3.6).  
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FIGURE3. 6. Suppression of RAD51 foci formation by CHK1 inhibition in 
hTERT-NHU cells following treatment with thymidine.   hTERT-NHU or 
HCT116 cells treated with 1mM thymidine in the presence or absence of the 
CHK1 inhibitor Gö6976 (1M) for 24h were fixed and stained for DNA content 
and RAD51. Images from immunofluorescence analysis represent RAD51 foci 
in hTERT-NHU or HCT116 cells treated with thymidine. The percentages of 
cells showing >10 RAD51 foci were scored.  
 
 
Bar graphs present the mean of at least three independent experiments 
+standard deviation of hTERT-NHU cells or HCT116 cells.  
 
In addition, the foci formed in the hTERT-NHU cells were less intense than 
those arising in HCT116 and they were sensitive to Gö6976, which indicates 
that even not fully activated ATR-CHK1 in some cells was able to induce 
formation of RAD51 foci. 
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Taken together, these data suggest that there is a lack of activation of the 
ATR-CHK1 signalling cascade in hTERT-NHU cells in response to DNA 
replication stress. 
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3.3.6 Reduction of CHK1 protein levels is accompanied by lower 
transcript levels. 
As described previously, CHK1 protein level was found to decrease in 
response to Gö6976 (Fig. 3.3A). As Gö6976 does not degrade protein level 
directly but only inhibit the CHK1 Ser296 autophosphorylation in response to 
DNA replication stress, the data has revealed a new question that where have 
the proteins gone? Recently, CHK1 was found to be ubiquitinated by the 
Skp1-Cul1-Fbx6 E3 ligase for proteasome-mediated degradation following 
phosphorylation of CHK1 at Ser345 in response to DNA replication stress 
(Zhang et al., 2009). Although there was no phosphorylation of CHK1 Ser345 
detected in hTERT-NHU cells in response to thymidine treatment, whether the 
lower total level of CHK1 in such cells was the result of proteasome associated 
degradation of CHK1 was still examined. hTERT-NHU cells were pre-treated 
with the proteosome inhibitor MG-132 followed by a exposure of Gö6976 and 
thymidine. Unlike the response of tumour cells (Wang et al., 2005), the lower 
CHK1 levels caused by Gö6976 treatment were not restored by treatment with 
MG-132 (Fig. 3.7A). Interestingly, qPCR analysis showed that Gö6976 treated 
hTERT-NHU cells had a more than 2-fold lower RNA level compared with 
untreated control (Fig. 3.7B). Thus the decrease CHK1 protein level detected 
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in response to treatment with the Gö6976 CHK1 kinase inhibitor appears to be 
the result of decreased transcription. 
 
FIGURE3. 7. Decreased CHK1 transcription in hTERT-NHU cells treated 
with CHK1 inhibitor.  (A) Western blot analysis of hTERT-NHU cells treated 
with Gö6976 (1M) for the indicated times in the presence or absence of the 
proteasome inhibitor MG132. pSer296 CHK1 is presented to confirm CHK1 
inhibition and -actin as loading control. (B) qPCR analysis of CHK1 
transcripts in hTERT-NHU cells grown in the presence or absence of Gö6976 
(1M) for 24h. 
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3.4  Discussion 
It has been well agreed that DNA damage response proteins regulate cell 
cycle progression in response to DNA damage or replication disruption. Many 
of these regulators are also important for optimal growth even in undisturbed 
cells. There have been many works from different laboratories shown that 
CHK1 not only regulates S-phase progression in cancer cells but also protects 
them from apoptosis in response to DNA replication stress (Meuth, 2010; 
Petermann et al., 2006; Rodriguez and Meuth, 2006; Sidi et al., 2008). 
However, the role of these checkpoint response proteins in “normal” epithelial 
cells is less clear. Here I investigated the response of primary and 
hTERT-immortalized NHU cells to variant DNA replication stresses. In contrast 
to many other reported studies with cancer cell lines, CHK1 inhibitors trigger 
very little cell death in response to DNA replication stress in both primary and 
hTERT-immortalized NHU cells. This indicates that although CHK1 is required 
for efficient progression of normal human urothelial cells through S-phase 
during DNA replication stress but it is not necessary to protect such cells from 
apoptosis.  
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In contrast to the response reported by other studies based on cancer cell lines, 
the data also suggest that CHK1 is only partially activated in hTERT-NHU cells 
following treated with a replication inhibitor. CHK1 is largely activated in 
response to ssDNA formation due to occurrence of functional uncoupled DNA 
polymerase and MCM helicase following replication inhibition (Byun et al., 
2005). This ssDNA is rapidly coated by RPA which then recruits ATR through 
the ATR interacting protein (ATRIP) (Zou and Elledge, 2003). The formation of 
this complex activates downstream CHK1 through phosphorylation at Ser345 
and Ser317 (Green et al., 2000; Zhao and Piwnica-Worms, 2001). Interestingly,  
this critical phosphorylation of CHK1 (on Ser345) in response to thymidine 
treatment is not found in hTERT-NHU cells. CHK1 S345A mutations result in 
impaired cell cycle checkpoints, loss of viability for proper localization and lead 
to apoptosis due to mitotic catastrophe in many types of cells(Shimada et al., 
2008; Walker et al., 2009; Wilsker et al., 2008). Thus since Chk1 S345 is 
essential for all functions of its kinase activity, the fai lure to phosphorylate this 
crucial site would be likely to severely reduce the CHK1-mediated checkpoint 
response.  
 
 
Chapter 3  The Response of Normal Urothelial Cells to CHK1 Inhibitors  
 
98 
 
The data suggest that this lack of Ser345 phosphorylation is because of the 
failure of hTERT-NHU cells to activate ATR in response to replication stress. It 
has previously been shown that RPA2 has a distinctive pattern of 
phosphorylation in many tumour cell lines in response to replication and CHK1 
inhibitors (Anantha et al., 2007; Liu et al., 2012). There is general agreement 
that Ser33 is a phosphorylation target for activated ATR (Anantha et al., 2007; 
Vassin et al., 2009). In contrast, Ser4/8 is mainly phosphorylated through ATM 
or DNAPK activity (Liu et al., 2012). Ser4/8 phosphorylation of RPA is usually 
found only in the most hyper-phosphorylated forms of RPA2 during DNA 
replication stress following phosphorylation of Ser33 which is phosphorylated 
by ATR (Anantha et al., 2007).  
 
Furthermore, when DNA replication is arrested, the stalled forks recruit a 
number of DNA repair associated proteins such as the homologous 
recombination repair protein RAD51 to resolve damage lesions and restart 
replication. RAD51 forms foci at stalled forks during DNA replication stress and 
this response has been strongly demonstrated as CHK1-dependent (Sorensen 
et al., 2005). Thus the lack of Ser33 phosphorylation and weak Rad51 foci in 
hTERT-NHU cells treated with thymidine in the presence or absence of CHK1 
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inhibitors combined with the Ser4/8 phosphorylation suggests that the 
ATR-CHK1 pathway is not fully activated in these cells and that ATM or 
DNAPK signalling takes the duty of the initial sensor in response to replication 
fork stress in these immortalized epithelial cells.  
 
Since Ser345 phosphorylation of CHK1 is required for the F box protein 
(Fbx6)-mediated degradation of CHK1 (Zhang et al., 2009), the absence of this 
phosphorylation in hTERT-NHU cells is likely to strengthen the stability of 
CHK1 during thymidine treatment. In contrast, treatment with Gö6976 down 
regulated CHK1 total protein level in either presence or absence of thymidine 
and a proteasome inhibitor failed to restore CHK1 levels. qPCR analysis 
indicated that the decrease of CHK1 is due to lower levels of CHK1 
transcription. This strongly suggests that CHK1 kinase activity may be required 
to maintain its own protein level in hTERT-NHU cells even in undisturbed cells. 
CHK1 has also previously been reported to dissociate from chromatin in 
response to DNA damage (Smits et al., 2006) and correlate with rapidly 
reduced phosphorylation of histone H3 on residue Thr11 (Klionsky et al., 2008).  
This has been shown to be necessary for facilitating the transmission of 
DNA-damage signals to downstream targets and repressing the transcription 
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of some regulators of cell cycle progression (Klionsky et al., 2008; Smits et al., 
2006), although the previous study did not reveal whether the CHK1 kinase 
regulated its own level. 
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Chapter 4 Activation of the Chk1 suppressed 
death in advanced malignant tumour cells under 
DNA replication stress 
4.1  Introduction 
The role of Chk1 in the cellular response to DNA replication stress is well 
examined. In addition to the regulation of cell cycle progression and checkpoint 
mechanism, recent studies reported a novel role of Chk1 in the suppression of 
apoptosis resulted from the disruption of DNA replication or DNA damage in 
variant tumour cell types (Cho et al., 2005; Rodriguez and Meuth, 2006; Sidi et 
al., 2008). ATR and Chk1 were showed to suppress apoptotic response by a 
caspase 3-dependent manner following DNA replication stress in both 
p53-proficient and -deficient cells (Myers et al., 2009). However, since Chk1 
has a number of roles in cells in response to DNA replication stress, the 
precise molecular mechanisms of how loss of CHK1 triggers apoptosis 
following replication disruption is sti ll not clear.  
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4.2  Aims and Hypothesis 
The role of Chk1 has been well characterised in various studies that Chk1 not 
only participates in cell cycle progression in undisturbed cells, but also in 
checkpoint system and protect tumour cells from cell death in response to DNA 
replication defects. This indicates a novel road toward cancer therapy. Thus, it 
is hypothesised that bladder tumour cells also show the reliance of cell survival 
on Chk1. In order to test the hypothesis and examine the potential role of 
CHK1 on targeted therapy in bladder cancers, various bladder cancer cell lines 
including two advanced malignant tumours Tcc-sup and EJ were investigated. 
In this present research, while cell cycle distribution and cell death were 
examined by flow cytometry, protein activation and total protein level changes 
were studied by immunoblotting. 
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4.3  Results 
4.3.1 Thymidine-induced DNA replication stress leads to S phase 
arrest with apparent cell death in Chk1 inhibited advanced bladder 
cancer cells. 
In the beginning, I tested the role of Chk1 in response to DNA replication stress 
in two different malignant bladder tumour cell lines. Consistent with other 
published reports that Chk1 plays a role in protecting cancer cells from cell 
death upon DNA replication defects (Gagou et al., 2010), treatment of bladder 
cancer cell lines (TCC-sup and EJ) with thymidine and Gö6976 produced very 
strong death effects of sub-G1 DNA content accumulation. Treatment of 
TCC-sup cells with Gö6976 or thymidine slowed S-phase transition with highly 
increased duplicated DNA content while a 24 or 48h co-treatment with these 
two inhibitors dramatically boosted levels of cells with a sub-G1 DNA content 
relative to cells treated with thymidine alone (Fig. 4.1A). Strikingly, even 
Gö6976 alone triggered a robust apoptotic response after only 24h with a high 
sub-G1 peak, but no accumulation in S-phase in EJ cells. When exposure to 
the combination of the two agents, the level of cells with sub-G1 DNA content 
was increased much further (Fig. 4.1A). 
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Tcc-sup, 24hr 
Tcc-sup, 48hr 
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FIGURE4.1A. Thymidine-induced DNA replication stress lead to S phase 
arrest with apparent cell death in Chk1 inhibited TCC-sup and EJ cells.  
Tcc-sup and EJ were pre-treated with 1M CHK1 inhibitor (Gö6976) for 2h and 
then incubated with or without 1mM thymidine for 24h or 48h before harvest 
and analysis for cell cycle distribution by flow cytometry. Values presented 
represent the mean of at least three independent experiments +standard 
deviation. *P<0.05 compared with untreated control cells. 
 
 
To ensure the sub-G1 DNA content was caused due to CHK1 
inhibition-induced apoptosis, caspase3 the marker of apoptosis was examined 
in response to the treatment as well. Consistently, the increased level of the 
sub-G1 population in EJ treated with Gö6976 was accompanied by a dramatic 
increase in the level of activated-caspase3 (Fig. 4.1B). 
EJ, 24hr 
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FIGURE4.1B. Thymidine-induced DNA replication stress lead to apparent 
cell death in Chk1 inhibited EJ cells.  Western blot analysis of 
activated-caspase3 in hTERT-NHU or EJ cells treated with 1M Gö6976 
and/or 1mM thymidine. -actin levels are presented as loading controls. 
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4.3.2 Thymidine-induced DNA replication stress leads to the 
classical ATR-Chk1 activation in EJ cells. 
I further examined the protein activation status and total protein levels of EJ 
cells in response to these treatments. It is commonly accepted that while 
CHK1 is rapidly phosphorylated at Ser345 and Ser317 in response to DNA 
damage or replication stress in a wide range of cells, the autophosphorylation 
site at Ser296 within the c-terminal regulatory domain (Clarke and Clarke, 
2005) is phosphorylated even in the absence of replication stress (Wilsker et 
al., 2008). Both Ser345 and Ser317 are critical for CHK1 kinase function as 
serine-to-alanine substitution mutations (S345A or S317A) that eliminate 
phosphorylation at these sites leading to suppress checkpoint activation and 
reduce viability (Shimada et al., 2008; Walker et al., 2009; Wilsker et al., 2008). 
In this case, cultures were exposed to thymidine in the presence or absence of 
Gö6976 pre-treatment for variant time points and harvested for Western blot 
analysis. Like the result obtained in normal human urothelial cell which was 
described in previous chapter, the elimination of Chk1 Ser296 expression in 
response to the treatment of CHK1 inhibitor confirmed the efficiency of the 
inhibitor. Consistent with other types of tumour cells, EJ bladder cancer cells 
show apparent phosphorylation of CHK1 at both Ser345 and Ser317 within 2h 
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of thymidine treatment. These events were further enhanced when tumour 
cells were co-treated with CHK1 inhibitor (Fig. 4.2A) whereas both 
phosphorylated- and total protein level of ATM were increased in response to 
DNA replication stress and not suppressed following Chk1 inhibition 
(presented in chapter 5). 
 
 
FIGURE4.2A. Western blot analysis of Chk1 activation in EJ cells treated 
with thymidine in the presence or absence of CHK1 inhibitor.  EJ cells 
were exposed to 1mM thymidine for 0-24h in the presence or absence of 1M 
Gö6976 before harvest and preparation of cell free extracts. Cells treated with 
Gö6976 were pre-incubated with the inhibitor for 2h before addition of 
thymidine, those treated with the CHK1 inhibitor alone (0h thymidine) were 
exposed for 24h. Western blots prepared from these extracts were analysed 
for Chk1. -actin levels are presented as loading controls. 
 
Furthermore, the Replication Protein A2 (RPA2) subunit of the RPA complex 
and histone H2AX were also reported to be phosphorylated in response to 
DNA replication disruption (Siegel et al., 2014; Syljuasen et al., 2005). The 
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data indicate that these events were further amplified in tumour cell lines 
treated with CHK1 inhibitors or siRNA (Fig. 4.2B). Although Chk2 Thr-68 and 
p53 Ser-15 phosphorylation were detected by immunoblotting, they do not 
seem to be the members participating in the checkpoint system that ATR-Chk1 
signalling cascades also plays, in response to thymidine-induced replication 
defects as CHK1 inhibited by Gö6976 does not result in obvious changes on 
their phosphorylation (Fig. 4.2B).  
 
FIGURE4.2B. Western blot analysis of DNA damage response proteins in 
EJ cells treated with thymidine in the presence or absence of CHK1 
inhibitor.  EJ cells were exposed to 1mM thymidine for 0-24h in the presence 
or absence of 1M Gö6976 before harvest and preparation of cell free extracts.  
Cells treated with Gö6976 were pre-incubated with the inhibitor for 2h before 
addition of thymidine, those treated with the CHK1 inhibitor alone (0h 
thymidine) were exposed for 24h. Western blots prepared from these extracts 
were analysed for the indicated damage response proteins. -actin levels are 
presented as loading controls.  
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4.3.3 Apparent cell death is triggered by gemcitabine in CHK1 
inhibited EJ cells upon DNA replication stress. 
In addition to thymidine, the effect of gemcitabine was also examined in 
Gö6976 treated EJ cells. Here the EJ cells were treated with 12.5 and 25nM 
gemcitabine for 24hr in the presence or absence of a 2hr pre-incubation with 
Gö6976. Consistent with the response triggered by thymidine, the 24h 
co-treatment with gemcitabine and Gö6976 induced significant sub-G1 DNA 
content in TCC-sup and EJ bladder cancer cells (Fig. 4.3). Notably, only 
gemcitabine or Gö6976 alone is enough to trigger death response in these two 
types of bladder tumour cells.  
 
Taken together, in contrast to hTERT-NHU cells, these data clearly show that 
the combination of DNA replication stress agent and CHK1 inhibition are able 
to produce a strong commitment to apoptosis in bladder cancer cell lines.  
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FIGURE 4.3. Gemcitabine induces apoptosis in bladder cancer cell lines 
when CHK1 is inhibited. TCC-sup and EJ bladder cancer cells were 
pre-treated with 1M Gö6976 for 2 h and then incubated with or without 
12.5nM Gemcitabine for 24h before harvest and analysis for cell cycle 
distribution by flow cytometry. Values presented represent the mean of at least 
three independent experiments +standard deviation. * P<0.05 compared with 
untreated negative control (NC) cells. 
  
Tcc-sup 
EJ 
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4.3.4 Neither thymidine nor gemcitabine induced significant 
death response in lower stage tumour cells combined with CHK1 
inhibition.   
In order to further examine the death response resulted from the combination 
of CHK1 deficiency and replication stress, more tumour cell lines including 
RT112, RT4, S637 and SW780 cell lines were screened as well. Compared 
with grade IV TCC-sup and invasive EJ cancer cells, these cell lines were 
much lower grade and not as malignant (RT4: papilloma, RT112: Grade I, 
SW780: Grade I, S637: Grade II) as TCC-sup and EJ according to neoplastic 
grading and TNM staging system. Similar to TCC-sup and EJ described 
previously, these bladder tumour cell lines were treated with thymidine in a 
dose-dependent manner for 24hr in the presence or absence of a 2hr 
pre-incubation with Gö6976. In contrast to Tcc-sup or EJ, only RT112 showed 
a small fraction of sub-G1 DNA content resulted from the treatments compared 
with untreated control, no significant difference of the pattern of sub-G1 
population was observed in other cell lines (Fig. 4.4A). 
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FIGURE4.4A. Thymidine was unable to induce significant apoptosis 
responses in lower grade bladder cancer cell lines (except RT112) when 
CHK1 is inhibited.  Five different types of lower stage bladder cancer cell 
lines were pre-treated with 1M Gö6976 for 2h and then incubated with or 
without thymidine as a dose-dependent manner for 24h before harvest and 
analysis for cell cycle distribution by flow cytometry. Bar graphs present the 
distributions of the cells in the different phases of the cell cycle. Values 
presented represent the mean of at least three independent experiments 
+standard deviation. * P<0.05 compared with untreated negative control (NC) 
cells. Note: The induction of sub-G1 populations in EJ cells serves as a positive 
control (presented as Fig. 4.1A)   
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Even when thymidine was replaced by the anti-cancer drug gemcitabine, only 
weak increases in apoptosis population was obtained in RT112 and RT4 cells 
when CHK1 was inhibited (Fig. 4.4B).  
 
 
FIGURE4.4B. Gemcitabine was unable to enhance apoptosis in RT112 
and RT4 bladder cancer cell lines when CHK1 is inhibited.  RT112 (left) 
and RT4 (right) bladder cancer cells were pre-treated with 1M Gö6976 for 2 h 
and then incubated with or without 12.5 and 25nM Gemcitabine for 24h before 
harvest and analysis for cell cycle distribution by flow cytometry. Bar graphs 
present the distributions of the cells in the different phases of the cell cycle. 
Values presented represent the mean of at least three independent 
experiments +standard deviation. * P<0.05 compared with untreated negative 
control (NC) cells. Note: The induction of sub-G1 populations in EJ cells serves 
as a positive control (presented as Fig. 4.3) 
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4.4  Discussion 
It is widely agreed that cell cycle checkpoint systems regulate cell cycle 
progression in response to DNA damage or replication defects to ensure 
genome stability. Many laboratories have reported that CHK1 not only 
regulates S-phase progression in tumour cells but also protects them from 
apoptosis following DNA replication stress (Meuth, 2010; Petermann et al., 
2006; Rodriguez and Meuth, 2006; Sidi et al., 2008). Consistently, this present 
study shows that the ATR/CHK1 pathway is activated in EJ and TCC-sup 
bladder cancer cells after treatment with replication inhibitor. Under replication 
stress CHK1seems dispensable for protection of these cells from apoptosis. 
However this survival dependence of CHK1 is not revealed in other bladder 
tumour cells. Why only EJ and TCC-sup show strong dependence on CHK1 
for cell survival under replication stress is still not clearly understood. It is 
suggested that different degrees of malignancy might be the reason. While 
TCC-sup is ranked as a grade IV transitional cell carcinoma of urinary bladder, 
it is also reported that EJ or previously called MGH-U1 cells is a subline and 
have the same origin as T-24 (Lin et al., 1985; O'Toole et al., 1983) which is a 
cell line established from a high grade transitional cell bladder carcinoma in 
1973 (Bubenik et al., 1973). In contrast, both RT4 and RT112 cells are only 
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well-differentiated, lowly proliferative and superficial grade I bladder cancer cell 
lines (Stravopodis et al., 2011). Similarly, the positive correlation between 
proliferation rate and drug sensitivity was also found in breast cancer that the 
clinical response of mostly DNA-targeted chemotherapy was significantly 
higher for rapidly than for slowly proliferating tomours (Amadori et al., 1997). 
Whether urothelial cells respond to chemotherapy via the similar mechanism 
needs more studies.  
 
Furthermore, p53 status in tumour cells may also play a role in survival 
dependence of ATR-CHK1 in response to DNA replication stress. In 
mammalian cells, ATR-CHK1-Cdc25 signalling cascades cooperate with 
ATM-CHK2-p53 pathway to ensure genome integrity in response to DNA 
damage or replication stress (Goto et al., 2012). The p53 tumour suppressor 
gene has already been reported to correlate with cell cycle checkpoint and 
determine cell fate. Activated and stabilized p53 triggers cell cycle arrest, cell 
senescence or apoptosis by regulating its downstream proteins including the 
Cdk inhibitor p21 or the pro-apoptotic BAX and PUMA proteins (McGowan, 
2002; Riley et al., 2008). In HCT116 colon cancer cells, cell survival was 
selectively reduced in p53-/- compared to p53+/+ cells in response to the 
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combination of UCN-01-induced CHK1 inhibition and IR (Petersen et al., 2010).  
The similar effect of cell survival was also obtained in osteosarcoma 
U2OS-VP16 cells with and without expression of p53 dominant-negative 
mutation (Petersen et al., 2010). Dicoumarol, a naturally occurring 
anticoagulant was also reported to suppress p53/p21 and enhance cytotoxicity 
of doxorubicin via p38 MAPK pathway in RT112 urothelial cancer cells (Matsui 
et al., 2010). Thus, loss of functional p53 may lead cells to rely more heavily on 
the other signalling pathway, ATR-CHK1, for cell survival in response to DNA 
damages or replication defects.   
 
It has been reported that most superficial urothelial cancers retain wild-type 
p53 and the mutation status were both associated with tumour grade and 
stage (Watanabe et al., 2004). Once p53 has mutated and lost its function, the 
ATR-CHK1 pathway then becomes the sole route of damage checkpoint in 
these cancer cells (Ma et al., 2011). This is consistent with the result described 
previously that only p53 mutated (EJ and TCC-sup) but not p53 wild-type 
bladder cancer cell lines (RT4, RT112, etc.) show prominent death response 
following DNA replication stress when CHK1 is inhibited. Taken together, it 
strongly suggests that p53-dependent cell cycle checkpoint may protect 
Chapter 4  Activation of the Chk1 Suppressed Death in Advanced Malignant 
Tumour Cells Under DNA Replication Stress 
 
120 
 
human bladder cancer cells from cell death in response to the treatment of 
DNA replication and Chk1 inhibitors. However, since p53 is proven to be a 
tumour suppressor gene and highly correlated to cell apoptosis, why p53 
deficient bladder tumour cell lines instead showed the prominent death 
response needs more studies. 
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Chapter 5 ATM regulates G1/S transition in 
normal urothelial cells and protects cell death in 
response to replication stress in tumour cells. 
5.1  Introduction 
ATM is a serine-threonine kinase (Abraham, 2001) with a large size of 370 
KDa and a member of the phosphatidylinositiol 3-kinase family. The function of 
ATM is well characterised due to the research of the disease Ataxia 
Telangiectasia (AT) which is a rare autosomal recessive disease resulted from 
mutation of ATM gene. Patients with homozygous ATM mutations show an 
early onset of progressive ataxia alongside other neurodegenerative 
conditions causing difficulty with movement and coordination (Lavin and Shiloh, 
1997). Mutated ATM genes in yeast, Drosophila and mammals also result in a 
variety of phenotypes with features similar to human AT cells (Savitsky et al., 
1995). ATM deficiency leads to growth retardation, infertility and 
cancer-predisposition in mice (Barlow et al., 1996). ATM mutated cells are 
highly sensitive to ionising radiation (IR) due to the defect of G1, S and G2/M 
arrest (Painter and Young, 1980). Since ATM is immediately activated in 
response to DNA damage and involved in the regulation of broad downstream 
substrates, defects of ATM affect a wide range of cell fate such as apoptosis or 
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tumourigenesis due to its function in DNA repair, cell cycle checkpoint, gene 
regulation,  translation initiation, and telomere maintenance (Kurz and 
Lees-Miller, 2004). It is generally accepted that ATR is activated due to the 
presence of single strand DNA (ssDNA) whereas ATM is triggered in response 
to DNA double strand breaks (DSBs). In response to DNA double strand 
breaks, ATM is recruited to the double strand ends by the three proteins 
Mre11, RAD50 and NBS1-formed complex (MRN complex) (Lee and Paull, 
2007) and phosphorylates the histone H2AX on Ser139 (Huang et al., 2004). 
ATM-CHK2 also phosphorylates phosphatase CDC25, which 
inactivates CDK-Cyclin complex resulting in cell-cycle arrest (Matsuoka et al., 
1998). If DNA DSBs are not repaired, ATM additionally 
phosphorylates MDM2 and p53 at Ser15 (Canman et al., 1998) leading to 
stabilization and activation of p53, which regulates numerous p53 target genes 
including Cdk inhibitor p21, proapoptotic proteins BAX, PUMA, and NOXA, 
and results in cell cycle arrest or apoptosis (Mirzayans et al., 2012). However, 
my lab has also taken the lead in demonstrating a novel role of ATM in 
response to DNA replication stress in the absence of DSBs. ATM deficient cells 
exposed to thymidine revealed a decrease of cell viability and failed to trigger 
homologous recombination repair (HRR) (Bolderson et al., 2004).  
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5.2  Aims and Hypothesis 
The generally accepted model is that ATR and ATM activated as an early 
regulator of either DNA replication arrest or DNA double strand breaks. In the 
previous chapters, the apparently distinct roles of ATR-CHK1 pathway was 
examined in normal human urothelial (NHU) cells versus bladder cancer cells. 
The ATR-CHK1 pathway is not fully activated in hTERT-NHU cells and only 
modestly affected after treatment with replication stressors. Since ATM and its 
downstream protein Chk2 are considered as regulators which participate in a 
pathway in parallel to ATR (Cliby et al., 1998) and shares some overlapping 
function such as Cdc25A phosphorylation (Falck et al., 2001; Zhao et al., 
2002), it is worthwhile to examine the relationship between ATM and ATR 
pathways particularly in DNA replication stress-induced checkpoint system. A 
hypothesis was proposed that ATM replaces ATR-CHK1 and acts as the major 
regulator in cell cycle progression in normal urothelial cells following replication 
defects. Treatments-induced protein phophorylation and total level changes 
were examined by Western blot. The role of ATM in cell cycle progression in 
response to replication stress was studied by FACS flow cytometry. DNA 
damage response proteins were tested by not only immunoblots but also 
immunofluorescence.    
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5.3  Results 
5.3.1 ATM is activated early by DNA replication stress in 
hTERT-NHU cells. 
To determine whether ATM is also activated in hTERT-NHU cells in response 
to replication inhibitors, cultures were treated with thymidine in the presence or 
absence of Gö6976 for different time points and harvested for Western blot 
analysis. Interestingly, in contrast to CHK1 described previously, ATM was 
autophosphorylated (at Ser1981) very early by 2hr after exposed to thymidine 
(Fig. 5.1).  
 
 
FIGURE5.1. Western blot analysis of ATM activation in hTERT-NHU cells 
treated with thymidine in the presence or absence of CHK1 inhibitor.  
hTERT-NHU cells were exposed to 1mM thymidine for 0-24h in the presence 
or absence of 1M Gö6976 before harvest and preparation of cell free extracts.  
Cells treated with Gö6976 were pre-incubated with the inhibitor for 2h before 
addition of thymidine, those treated with the CHK1 inhibitor alone (0h 
thymidine) were exposed for 24h. Western blots prepared from these extracts 
were analysed for ATM activation. -actin levels are presented as loading 
controls. 
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Downstream phosphorylation targets of activated ATM (pThr68 CHK2 and 
pSer15 p53) were also examined in hTERT-NHU cells after exposed to 
thymidine treatment as described previously (Fig. 3.3B, 3.3C). These events 
look independent of thymidine-induced CHK1 activation as they were not 
affected by Gö6976 caused CHK1 inhibition.  
 
  
Chapter 5  ATM Regulates G1/S Transition in Normal Urothelial Cells and 
Protects Cell Death in Response to Replication Stress in Tumour Cells 
 
128 
 
5.3.2 ATM kinase activity is required for G1-S phase transition in 
hTERT-NHU cells but not S-phase progression. 
Since ATM showed the relatively early activation following thymidine treatment 
in the presence or absence of Chk1 inhibitor, the effect of ATM inhibition on 
immortalized normal urothelial cells during DNA replication stress was then 
examined. hTERT-NHU cells were firstly treated with 10 M of the highly 
specific ATM inhibitor KU55933 (Hickson et al., 2004) for 2 hr and then 
incubated in the presence or absence of thymidine or gemcitabine for 24hr. 
Cells were harvested for cell cycle analysis by FACS. As expected, there was 
almost no cell death detected due to the treatment. Interestingly, the fraction of 
cells in S phase was significantly reduced following KU55933 treatment no 
matter in the presence or absence of thymidine or gemcitabine relative to 
untreated control (Fig. 5.2A, B). This response was further confirmed in 
primary NHU cells. Primary NHU cells showed a similar reduction of S-phase 
population following treated with KU55933 in both presence or absence of 
thymidine treatment (Fig. 5.2C). Additionally, a second ATM specific kinase 
inhibitor resulted in similar results with reduced S-phase fraction (Fig. 5.2D).  
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FIGURE5.2. Active ATM is essential for G1 to S phase progression in 
hTERT-NHU cells.  hTERT-NHU cells were pre-incubated with 10M 
KU55933 for two hours before addition of 1mM thymidine (A) or 12.5nM 
gemcitabine (B). After 24h cells were harvested for analysis by flow cytometry. 
Values presented represent the mean of at least three independent 
experiments +standard deviation. * P<0.05 compared with untreated negative 
control (NC) cells.  
 
A 
B 
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FIGURE5.3. Active ATM is essential for G1 to S phase progression in 
hTERT-NHU cells.  (C) Primary NHU cells were pre-incubated with 10M 
KU55933 for two hours before addition of 1mM thymidine. After 24h cells were 
harvested for analysis by flow cytometry. (D) hTERT-NHU cells were treated 
with KU60019 as dose dependent manner. Values presented represent the 
mean of at least three independent experiments +standard deviation. * P<0.05 
compared with untreated negative control (NC) cells.  
 
C 
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To further determine whether the effect of the ATM inhibitor was restricted to 
cells entering S-phase, hTERT-NHU cells were first treated with KU55933 and 
then incubated with the mitotic inhibitor nocodazole to trap cycling cells 
entering G2/M phase. As shown in the results, the combination of ATM inhibitor 
and nocodazole not only reduced the level of S-phase cells but also increased 
the number in G2/M relative to untreated control (Fig. 5.3). This may due to the 
fact that the cells already in S-phase successively progressed into G2/M where 
they were arrested by nocodazole treatment and no new cells were able to 
enter S phase. 
 
FIGURE5.4. Effect of Nocodazole on hTERT-NHU cells in the presence or 
absence of ATM inhibitor.  hTERT-NHU cells were treated with nocodazole 
(right panels) in the presence or absence of 10 M KU55933 (bottom panels) 
for 24h before harvest and analysis for DNA content by flow cytometry. Bar 
graph shows the mean values of the percentages of cells in the different 
phases of the cell cycle. Values presented represent the mean of at least three 
independent experiments +standard deviation. * P<0.05 compared with 
untreated negative control (NC) cells. 
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Consistently, the fraction of cells incorporating BrdU indicated that they had 
difficulty entering S-phase with very low levels of BrdU+ cells in response to the 
treatment of KU55933 particularly by 24hr (Fig. 5.4). 
 
FIGURE5.5. Analysis of BrdU incorporation on ATM inhibitor pre-treated 
hTERT-NHU cells.  hTERT-NHU clls treated with KU55933 for the indicated 
times were labelled with BrdU for 2h before harvest and analysis of BrdU 
incorporation by flow cytometry. Values presented represent the mean of at 
least three independent experiments +standard deviation. * P<0.05 compared 
with untreated negative control (NC) cells. 
 
hTERT-NHU cells were also pre-labelled with BrdU for 2h followed by addition 
of ATM inhibitor to examine the fate of cells already in S-phase. Cells were 
then harvested 24h after addition of KU55933 and analysed for both DNA 
content and BrdU incorporation. In both groups with presence or absence of 
the ATM inhibitor, labelled cells successively progressed through S-phase and 
ATM inhibitor pre-treated hTERT-NHU cells with BrdU lebeling
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they were present in both G2/M and G1 after 24hr suggesting that the ATM 
inhibitor had little effect on S or G2/M phase. However, almost no BrdU 
incorporation could be found in S-phase cells once ATM was inhibited for 24hr 
in hTERT-NHU cells indicating that ATM inhibition triggered G1 phase 
checkpoint and blocked S-phase entry (Fig. 5.5).  
 
FIGURE5.6. The ATM inhibitor does not stop progression of hTERT-NHU 
cells through S- or G2/M phases.  hTERT-NHU cells pre-labelled with BrdU 
(10mM) were incubated in the presence or absence of KU55933 (10M) for 
24h. Cells were then harvested and analysed for BrdU incorporation and DNA 
content. Cells in S-phase at the time of BrdU labelling progressed through 
S-phase and into G2/M and G1 in the presence or absence of the ATM inhibitor. 
Values presented represent the mean of at least three independent 
experiments +standard deviation. * P<0.05 compared with untreated negative 
control (NC) cells. 
 
Taken together, these data indicate that ATM kinase activity is required for 
S-phase entry in hTERT-NHU cells but not for progression through S- or 
G2/M-phases. 
Untreated ATM inh. 
Untreated ATM inh. 
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5.3.3 ATM kinase plays a role upstream of CHK1 checkpoint 
pathway. 
Alteration of protein activation and total protein levels in response to ATM 
inhibition were also examined. Western blot analysis of extracts prepared from 
hTERT-NHU cultures showed that the ATM inhibitor KU55933 suppressed the 
thymidine treatment –induced autophosphorylation of ATM at Ser1981 
confirming the effectiveness of the inhibitor (Fig. 5.6A). 
 
FIGURE5.7A. Analysis of ATM activation in hTERT-NHU cells treated with 
thymidine in the presence or absence of the ATM inhibitor.  hTERT-NHU 
cells were incubated from 0-24h with 1mM thymidine in the presence or 
absence of 10M KU55933 before harvest and preparation of cell free extracts.  
Cells treated with KU55933 were pre-incubated with the inhibitor for 2h before 
addition of thymidine, those treated with the ATM inhibitor alone (0h thymidine) 
were exposed for 24h. Western blots prepared from these extracts were 
analysed for the activated and total protein level of ATM. -actin levels are 
presented as loading controls. 
 
Notably, even though total Chk1 level did not seem to down regulate in 
response to ATM inhibition, thymidine-induced Ser317 and Ser296 Chk1 
phosphorylation were suppressed after treatment with KU55933 suggesting 
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that ATM activation may play a role upstream of Chk1, which regulates Chk1 
phosphorylation. Furthermore, Ser15 phosphorylated forms of p53 and protein 
level also decreased under these conditions relative to cells treated with 
thymidine alone. Unlike CHK1 inhibited hTERT-NHU cells, thymidine treated 
hTERT-NHU cells failed to phosphorylate RPA and -H2AX following addition 
of ATM inhibitor KU55933 by 24h (Fig. 5.6B). 
 
FIGURE5.6B. Analysis of DNA damage response and cell cycle 
regulatory proteins in hTERT-NHU cells treated with thymidine in the 
presence or absence of the ATM inhibitor.  hTERT-NHU cells were 
incubated from 0-24h with 1mM thymidine in the presence or absence of 10M 
KU55933 before harvest and preparation of cell free extracts. Cells treated 
with KU55933 were pre-incubated with the inhibitor for 2h before addition of 
thymidine, those treated with the ATM inhibitor alone (0h thymidine) were 
exposed for 24h. Western blots prepared from these extracts were analysed 
for the indicated damage response proteins. -actin levels are presented as 
loading controls. Note: Expression of p-Chk1 Ser345 in EJ cells serves as a 
positive control (presented as Fig. 4.2A, Chapter 4).  
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5.3.4 RPA or -H2AX foci were not induced in hTERT-NHU cells 
treated with ATM inhibitor. 
Additionally, in consistent with the Western blot analysis described previously 
(Fig. 5.6B, 5.7A), there was no further increase of cells which formed RPA or 
-H2AX foci in response to the combined treatment of the two agents relative 
to cells treated with thymidine or KU55933 alone (Fig. 5.7B). Compared with 
chemical inhibition of the kinase inhibitor, HCT116 was considered as a 
positive control with its siRNA-caused cellular protein depletion. 
 
 
FIGURE5.8A. Western blot analysis of RPA phosphorylation in 
hTERT-NHU cells treated with thymidine in the presence or absence of 
ATM inhibitor.  Western blot analysis of phosphorylated forms of RPA2 in 
extracts prepared from hTERT-NHU cells treated with 1mM thymidine for 24h 
with or without KU55933 (10M). HCT116 cells treated with CHK1 siRNA and 
thymidine were generously gifted by Dr. Zuazua-Villar and presented as a 
positive control for full hyperphosphorylation of RPA2 (Gagou et al., 2010; 
Rodriguez et al., 2008).  
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FIGURE5.7B. Immunofluorescence analysis of RPA and -H2AX foci in 
hTERT-NHU cells treated with thymidine in the presence or absence of 
ATM inhibitor.  Representative images from immunofluorescence analysis of 
RPA and -H2AX foci in hTERT-NHU cells treated with 1mM thymidine and 
1M KU55933.  
 
Chapter 5  ATM Regulates G1/S Transition in Normal Urothelial Cells and 
Protects Cell Death in Response to Replication Stress in Tumour Cells 
 
138 
 
 
Bar graphs present the mean of at least three independent experiments 
+standard deviation of hTERT-NHU cells treated with 1mM thymidine for 24h 
with or without KU59935 (10M). Foci images of hTERT-NHU cells treated 
with Chk1 inhibitor and thymidine serve as positive controls (presented as Fig. 
3.4, Chapter3). 
 
Furthermore, the fraction of cells forming RAD51 foci following thymidine 
treatment was significantly reduced by treating with ATM inhibitor (Fig. 5.7C). 
These results strongly suggest that ATM is necessary for S-phase entry and 
consistent with the conclusion that hTERT-NHU cells fail to enter S-phase after 
treatment with the ATM inhibitor. 
RPA -H2AX 
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FIGURE5.7C. Suppression of RAD51 foci formation by ATM inhibition in 
hTERT-NHU cells following treatment with thymidine.   hTERT-NHU or 
HCT116 cells treated with 1mM thymidine in the presence or absence of the 
ATM inhibitor KU55933 (10M) for 24h were fixed and stained for DNA content 
and RAD51. Images from immunofluorescence analysis represent RAD51 foci 
in hTERT-NHU or HCT116 cells treated with thymidine.  
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The percentages of cells showing >10 RAD51 foci were scored. Bar graphs 
present the mean of at least three independent experiments +standard 
deviation of hTERT-NHU cells or HCT116 cells.   
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5.3.5 ATM inhibition triggers a G1 checkpoint hTERT-NHU cells. 
How ATM inhibition regulates the S phase entry was next examined. In 2004 
there is a paper reported that ATM normally controls the generation of reactive 
oxygen species (ROS). If ATM function is lost, p16INK4a is induced by ROS 
and this inhibits the CDK-mediated phosphorylation of retinoblastoma (RB) 
necessary for the S entry. Thus ATM inhibition triggers a G1 checkpoint that 
can be relieved by treatment with ROS inhibitors (Ito et al., 2004). To 
determine whether a similar mechanism was responsible for G1-S phase 
transition, the ROS inhibitor N-Acetylcysteine (NAC) was tested in 
hTERT-NHU cells. However ATM suppression-induced block of S-phase entry 
was not rescued by the treatment of NAC in hTERT-NHU cells (Fig. 5.8). 
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FIGURE5.9. Induction of G1 arrest by the ATM inhibitor in hTERT-NHU cells is 
not rescued by an ROS inhibitor.  hTERT-NHU cells exposed to the ATM 
inhibitor for 24h in the presence or absence of the ROS inhibitor 
N-acetylcysteine (100M) were harvested for analysis of cell cycle distribution 
by flow cytometry. A representative profile of such an analysis is presented 
together with a bar graph presenting the distributions of the cells in the 
different phases of the cell cycle. Values presented represent the mean of at 
least three independent experiments +standard deviation. * P<0.05 compared 
with untreated negative control (NC) cells. 
 
To further examine whether the failure of hTERT-NHU cells to enter S-phase 
was due to an induction of a G1 checkpoint, G1 checkpoint associated proteins 
were analysed in cells treated with ATM inhibitor. As shown in the result, levels 
of p16INK4a did not show any apparent change following exposure to KU55933 
in the presence or absence of thymidine (Fig. 5.9), however the level of 
another cyclin-dependent kinase inhibitor p19 INK4D appeared an dramatic 
increase and the CDK4/6-mediated phosphorylation of RB that is normally 
triggered when cells entering S-phase was reduced in cells following treated 
with KU55933. Additionally Cyclin D1 and CDK4 levels were down regulated in 
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cells treated with KU55933, which is consistent with an arrest in G1 (Baldin et 
al., 1993). In contrast, the level of another CDK-inhibitor (CDKN1A, p21) was 
not increased in cells treated with the ATM inhibitor (Fig. 5.9). Taken together 
these results suggest that hTERT-NHU cells fail to enter S-phase after 
treatment with the ATM inhibitor as a result of the activation of a G1 checkpoint. 
 
FIGURE5.10. Analysis of cell cycle regulatory proteins in hTERT-NHU 
cells treated with thymidine in the presence or absence of the ATM 
inhibitor.  hTERT-NHU cells treated with 10M KU55933 or 1M Gö6976 
inhibitors in the presence or absence of 1mM thymidine for 24h were 
harvested and analysed for the indicated cell cycle regulators by Western 
blotting. -actin levels are presented as loading controls. 
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5.3.6 EJ bladder cancer cells show enhanced apoptosis after 
treatment with the ATM inhibitor and thymidine. 
The effect of ATM inhibition on malignant bladder cancer cells was also 
examined. When EJ cancer cells were treated with KU55933 alone, the 
population of S-phase cells significantly increased compared to untreated cells 
however only few cells with sub-G1 DNA content were detected (Fig. 5.10A). In 
response to combined treatment of KU55933 and thymidine, the fraction of 
cells with a sub-G1 DNA content increased dramatically accompanied by a 
decreased level of S- and G2/M-phase cells. This sign of cell death was further 
confirmed by activation of caspase3 (Fig. 5.10A, 5.10B) following the 
combination of KU55933 and thymidine treatment compared to cells treated 
with thymidine alone. Thus, in striking contrast to the hTERT-NHU cells 
described previously, ATM inhibition not only slows cell cycle progression 
through S-phase but also strongly commits EJ cells to apoptosis in response to 
DNA replication stress. 
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FIGURE5.11. Active ATM protects EJ bladder cancer cells from death 
during replication stress.  (A) EJ bladder cancer cells were pre-incubated 
with KU55933 (10M) for two hours before addition of 1mM thymidine. Cells 
were harvested at 24h for analysis by flow cytometry. (B) Western blot analysis 
of EJ cells treated as above for caspase3 activation. 
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5.3.7 DNA replication was able to restart in hTERT-NHU cells 
when they were released from CHK1 or ATM inhibition. 
In this study, the combination of CHK1/ATM inhibition and DNA replication 
were demonstrated to be able to selectively kill tumour cells with only some 
slight alteration on normal urothelial cells. So far there are many reports 
claimed that their “targets” of cancer therapy are able to specifically ki ll tumour 
cells, however data were shown that most of those treatments exists some 
side effects such as irreversible cell senescence on non-tumour cells. Thus, it 
is important to see whether the effects on non-targeted cells were reversible or 
not. hTERT-NHU cells were pre-incubated with CHK1/ATM inhibitor for 2h 
followed by a 24h thymidine treatment. Cells were then released from 
treatments with fresh medium for another 24h and pulsed with BrdU for 2h 
before harvest and analysis of BrdU incorporation and DNA content by FACS. 
Here the treatment-induced cell cycle alteration seems able to be restored 
once they escaped from the inhibition. Although cells treated with thymidine in 
the presence of the CHK1 inhibitor show a little evidence of cell cycle re-entry, 
cells treated with ATM, CHK1 or replication inhibitors alone were demonstrated 
largely able to resume DNA replication particularly those released from ATM 
inhibition showed very high S phase DNA content (Fig. 5.11). 
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FIGURE5.12. DNA replication was resumed after released from inhibition.  
hTERT-NHU cells were treated with the 1mM thymidine with or without CHK1 
inhibitor Gö6976 (1l) or ATM inhibitor KU55933 (10M) for 24h before 
removal of the inhibitor and transfer to inhibitor-free medium for a further 24h. 
The treated cells along with untreated control cells (grown in inhibitor-free 
medium for the full 48h) were labelled with BrdU (10M) for 2h before harvest 
and analysis of DNA content and BrdU incorporation by flow cytometry. The 
bar graph presents the distributions of the cells in the different phases of the 
cell cycle. Values presented represent the mean of at least three independent 
experiments +standard deviation. * P<0.05 compared with untreated negative 
control (NC) cells.  
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5.3.8 The potential interaction between ATM inhibition and 
autophagocytosis. 
Intriguingly, there was an autophagy-like (bubbles and granules formation) 
morphological changes shown within ATM inhibitor-incubated hTERT-NHU 
cells after a 2hr treatment but not in other treated groups (Fig. 5.12A).  
   
FIGURE5.13A. ATM inhibitor treatment resulted in autophagy-like 
morphological alteration.  hTERT-NHU cells were treated with the 1mM 
thymidine with or without CHK1 inhibitor Gö6976 (1l) or ATM inhibitor 
KU55933 (10M) for 24h and observed by 20X object lens of microscope 
directly.  
 
Autophagy is a mechanism that cell degrades its unnecessary or dysfunctional 
cellular organs by lysosomes to maintain cellular energy levels for cell survival 
in response to starvation or stresses. Recently, ATM activation was reported to 
be necessary in ROS-induced autophagy in MCF7 cells (Alexander et al., 
Untreated Chk1 inh. ATM inh.
Thymidine Chk1 inh. + TdR ATM inh. + TdR
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2010a; Alexander et al., 2010b) and also required for self-renewal of 
haematopoietic stem cells (Ito et al., 2004). In the past decade, it has been 
published that the rat microtubule-associated protein 1 light chain 3 (LC3) is 
associated to the autophagosome membranes formation and essential for 
autophagy. During the process of autophagy, the cytosolic LC3-I was 
converted to membrane bound LC3-II (Kabeya et al., 2000). Therefore the 
increasing level of LC3-II was widely accepted as a powerful marker of 
autophagy.  
 
To examine whether this ATM suppression-induced morphological changes 
resulted from autophagy and associated with ROS, the alteration of LC3 
protein in response to ATM inhibition with or without the ROS inhibitor NAC 
were tested. However in this case, although the level of LC3-II increased 
dramatically, no evidence of the decrease of LC3-1 was shown in response to 
KU55933 caused ATM inhibition (Fig. 5.12B). Furthermore, this ATM inhibitor 
treatment-induced morphological aberration also could not be rescued by 
pre-incubation of the ROS inhibitor NAC (Fig. 5.12C).  
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FIGURE 5.12B, C. ATM inhibitor treatment-induced morphological 
alteration is independent with autophagy or reactive oxygen species 
(ROS).  (B) hTERT-NHU cells treated with the 1mM thymidine with or without 
ATM inhibitor KU55933 (10M) for 24h were harvested and analysed for the 
marker of autophagy, LC3 by Western blotting. 100 uM 5hr repamycin-treated 
MCF-7 served as positive control (Klionsky et al., 2008; Klionsky et al., 2007). 
-actin levels are presented as loading controls. (C) hTERT-NHU cells treated 
with the ATM inhibitor KU55933 (10M) for 24h with or without the ROS 
inhibitor NAC (100M) pre-incubation were observed by 20X object lens of 
microscope directly.  
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The cell cycle analysis and bar graph presents the distributions of the cells in 
the different phases of the cell cycle. Values presented represent the mean of 
at least three independent experiments +standard deviation. * P<0.05 
compared with untreated negative control (NC) cells. 
 
Altogether, ATM inhibition-induced morphological changes in hTERT-NHU 
cells seem to be independent of autophagy or reactive oxygen species. 
Unfortunately, where those cellular granules and bubbles come from is still a 
mystery. The details of how ATM might participate in epithelial cell 
re-programming need more studies.  
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5.4  Discussion 
ATM has previously been reported to play a novel role in response to DNA 
replication stress in the absence of DSBs (Bolderson et al., 2004). Here the 
data further confirm that ATM is activated as an early regulator in hTERT-NHU 
cells in response to thymidine caused replication stress. While ATM activation 
has widely been recognised as the sensor of DSB formation, other pathways 
that repair stalled replication forks could generate the transient double-strand 
ends that activate ATM. For instance stalled forks in such cells under 
replication stress may be more likely to regress and generate a “chicken foot 
structure” which forms transient DNA ends or breaks during the resolution of 
stalled forks could potentially trigger ATM activation (Courcelle et al., 2003; 
Petermann and Helleday, 2010).  
 
Intriguingly, in addition to the role as an early regulator following DNA 
replication stress in hTERT-NHU cells, ATM inhibition is also demonstrated to 
triggers a G1 checkpoint that controls S-phase entry. This answers the 
question of why no Ser4/8 phosphorylation was detected following treated 
ATM inhibitor under these conditions and potentially indicates that functional 
ATM signalling transduction pathway was crucially responsible for this 
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phosphorylation. However the deficiency in Ser4/8 RPA2 phosphorylation may 
simply be due to a failure of cells treated with the ATM inhibitor to enter 
S-phase. Although the role of ATM in the activation of the G1-S checkpoint in 
response to DNA double-strand breaks has been well studied, the requirement 
for ATM in the G1-S transition in unstressed cells is still poorly understood.  
 
Notably ATM was found to play a role in regulating oxidative stress, which is 
necessary for the self-renewal of mouse haematopoietic stem cells (Block et 
al., 2004). p16INK4a is activated by an accumulation of reactive oxygen species 
(ROS) in cells derived from ATM-/- mice and in turn inhibits RB phosphorylation 
which leads to the block of S-phase entry. In hTERT-NHU cells although RB 
phosphorylation was reduced after treatment with the ATM inhibitor, there was 
no p16INK4a accumulation detected and the ROS inhibitor NAC did not reverse 
the G1 block. In contrast, the levels of the CDK4/6 inhibitor p19
INK4D increased 
accompanied reduced levels of cyclin D1 and CDK4 under these conditions. 
These alterations are consistent with the G1 checkpoint activation that restricts 
S-phase entry. Why ATM is required for the G1/S-phase transition needs 
further studies. In 2005, the induction of p19INK4D in response to ultraviolet light 
in neuroblastoma cells was reported to enhance UV-induced repair and protect 
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cells from apoptosis (Ceruti et al., 2005), this may point out a possibility that 
ATM protects these cells from some sort of ROS independent endogenous 
DNA damages. However, since p19 INK4D can also be induced by the hormonal 
form of vitamin D3 and retinoids leading to cell cycle arrest (Tavera-Mendoza 
et al., 2006), the induction of p19 INK4D may simply due to that ATM participates 
in regulation of growth signal transduction pathway for the bladder epithelial 
cells. In contrast to hTERT-NHU cells, the ATM requirement for S-phase entry 
was not shown in bladder cancer cell lines as these cells accumulated in 
S-phase following treated with the ATM inhibitor and committed to apoptosis in 
response to the combination of ATM and replication inhibitors. Thus this may 
be a consequence of disruptions of the G1/S checkpoint caused by defects of 
the RB pathway that are commonly found in tumourigenesis (Di Fiore et al., 
2013) or just because the novel role for ATM has lost during the development 
of bladder cancers.   
  
Replication stress or DNA damage is increased during oncogenic 
transformation, which makes them more dependent upon DNA damage 
response pathways for cell survival (Bartkova et al., 2006; Bester et al., 2011; 
Vafa et al., 2002) . To cope with this stress many tumour cell lines elevate 
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levels of CHK1 and show dependence on it for protection from apoptosis under 
DNA replication stress (Verlinden et al., 2007). In addition to Chk1, this study 
finds that some highly malignant bladder tumour cell lines also showed 
dependence upon ATM to protect them from apoptosis. Although a 
combination of ATM and replication inhibitors may provide a novel route to 
selectively kill bladder cancer cells with no damage on normal urothelial cells, 
there is no doubt that further studies will be required to examine which type of 
tumour cells are more favourable in response to such therapies. Taken 
together, ATM/Chk1 may be an attractive target for clinical anti-cancer therapy 
as DNA replication stress-induced cell death is specific to ATM/Chk1 
suppressed tumour cells but not normal urothelial cells. The most important of 
all, this therapeutic is reversible in normal non-tumour cells. 
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Chapter 6 Discussion 
6.1  Introduction 
Chk1 plays a critical role in cell cycle progression in response to DNA damage 
or even in undisturbed cells. In the past decade, the function of Chk1 in 
response to DNA replication stress has been well established in tumour cells 
or normal fibroblasts. DNA replication stress has been demonstrated to be 
cytotoxic to Chk1 depleted tumour cells. Furthermore, ATM was previously 
reported to play a role in Chk1 regulation. However, the effect of Chk1 
inhibition and the correlation between ATM and Chk1 in “normal” cells are still 
not clearly understood. In this study, the novel roles of Chk1 and ATM are 
shown in normal urothelial cells. 
 
6.1.1 Loss of CHK1 or ATM results in cell death in response to 
DNA replication stress in tumour cells but not in normal urothelial 
cells. 
Consistent with many other studies, Chk1 inhibition by Gö6976 in EJ bladder 
cancer cells led to serious cell death indicates that tumour cell survival may be 
dependent on ATR-Chk1 particularly following DNA replication stress (Meuth, 
2010; Myers et al., 2009). However, this dependence was not found in primary 
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or hTERT immortalized epithelial-like NHU cells. While EJ or TCC-sup bladder 
cancer cell lines showed evident death response, Chk1 inhibition in 
hTERT-NHU cells only slows S-phase progression in response to thymidine 
treatment-induced DNA replication stress, but does not trigger cell apoptosis 
 
As described previously in the chapter of introduction, Chk1 serves as a work 
horse even in undisturbed cells for cell cycle progression. However in many 
malignant tumour cells Chk1 has been demonstrated to play a role in 
protecting cells from death in response to DNA replication stress. Hence it is 
not surprising that DNA replication inhibitors thymidine or gemcitabine 
triggered serious cell apoptosis in Chk1 inhibited TCC-sup and even more 
robust death response in EJ bladder tumour cells. In contrast, normal urothelial 
cells do not appear to exhibit a similar dependence. Neither totally primary 
NHU nor human telomerase reverse transcriptase (hTERT) transfected 
hTERT-NHU cells show cell death in response to this similar treatment.  
 
Furthermore, ATM is found to protect EJ cells as well as Chk1 from replication 
stress-induced cell apoptosis. Unlike hTERT-NHU cells, EJ fully activates 
classical DNA damage response pathways with both Ser345 Chk1 and 
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Ser1981 ATM phosphorylation. When Chk1 kinase activity is suppressed by 
Chk1 inhibitor Gö6976, the Ser1981 phosphorylated ATM undergoes a 
dramatic increase in response to genotoxic stress in EJ cells. This is 
consistent with the report that Chk1 inhibition activates an ATM and 
DNA-dependent protein kinase (DNAPK)-mediated double strand break 
response under replication defects. Checkpoint abrogated cells result in 
ATM and DNA-PK, but not ATR mediated -H2AX induction and lethally 
premature mitosis entry following gemcitabine treatment (McNeely et al., 
2010). Thus a DNA replication stress agent like gemcitabine seems to be able 
to selectively kill highly malignant but not normal urothelial cells after CHK1 or 
ATM inhibition. 
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6.1.2 CHK1 Ser345 is not the major regulator in normal urothelial 
cells under DNA replication stress. 
It was also found that ATM, but not ATR plays a more important role in 
hTERT-NHU cells. ATM serves as an early checkpoint in this cell model in 
response to DNA replication stress and a key regulator of S-phase entry. 
Although some other groups reported that ATR activation and some ATR 
downstream proteins can be regulated by ATM. Both ATM (pSer-1981) 
and Chk1 (pSer-345), but neither ATR (pSer-428) nor Chk2 (pThr-68) are 
activated in mouse zygotes fertilized with H₂O₂-treated sperm to trigger cell 
cycle arrest to provide time for sperm-derived DNA-damage repair (Wang et 
al., 2013). ATM has also been found able to regulate a direct ATR activator 
TopBP1 by phosphorylation on Ser-1131 in Xenopus egg extracts. A mutation 
that restricted phosphorylation at TopBP1 at this site, produced a 
defective ATR-dependent activation of Chk1 in response to DNA damage (Yoo 
et al., 2007). However this ATM-mediated ATR activation does not appear to 
be responsible for thymidine-induced DNA replication stress in hTERT-NHU 
cells. Since Chk1 Ser345 phosphorylation site is well known to be a key 
downstream regulator in response to activated ATR, it is not detected in 
hTERT-NHU cells followed by thymidine treatment. Additionally, there is no 
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RPA Ser33 phosphorylation, the major phosphorylation site of ATR, but Ser4/8 
phosphorylation of RPA2 can be observed following thymidine treatment. 
These data suggest that the ATR-Chk1 pathway does not respond in these 
cells and that ATM or DNAPK signalling cascades may play the initial response 
to DNA replication stress in normal urothelial cells. 
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6.1.3 The role of RPA hyper-phosphorylation in DNA replication 
stress. 
In HCT 116 colon tumour cells, RPA hyper-phosphorylation after 
thymidine-induced DNA replication stress was found in Chk1 inhibited cells. 
However this hyper-phosphorylated form of RPA was not apparently induced in 
hTERT-NHU cells even treated with both thymidine and Chk1 inhibitor. 
Unfortunately, so far the role of RPA hyper-phosphorylation is still not clearly 
understood. Two possible mechanisms of RPA hyper-phosphorylation were 
previously hypothesized (Zou et al., 2006). First, the hyper-phosphorylation of 
RPA may serve the recognition by hyper-phosphorylation binding proteins. It is 
possible that the hyper-phosphorylation of RPA is required for regulation of 
proteins such as checkpoints in response to different genetic stresses. Second, 
RPA hyper-phosphorylation results in protein structure transformation and 
leads to the disruption of RPA-DNA and RPA-protein interactions (Zou et al., 
2006). It is possible that the checkpoint-induced RPA hyper-phosphorylation 
may down regulate the DNA replication initiation and also suppress 
recombination as hyper-phosphorylation mimicking RPA is not able to 
associate with replication centres in vivo (Vassin et al., 2004). 
  
Chapter 6  Discussion 
 
163 
 
6.1.4 The potential interaction between ATM and RPA 
phosphorylation 
In this study, it has been found that ATM acts an early regulator rather than 
ATR-Chk1 in response to thymidine treatment-induced DNA replication stress 
in hTERT-NHU cells. Although RPA has already been reported to coat ssDNA 
and recruit ATR to trigger ATR-CHK1 checkpoint signalling pathway during 
replication stress (Zou and Elledge, 2003), it remains unclear that whether 
RPA is also involved in ATM-dependent checkpoint cascades. Here I showed 
that the ATM inhibitor is able to suppress RPA Ser4/8 phosphorylation directly 
under these conditions, suggesting that the ATM signalling pathway may 
participate in this phosphorylation although the deficiency of RPA Ser4/8 
phosphorylation is most likely due to the failure such cells to enter S-phase. 
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6.1.5 The expression of -H2AX in combined treatment of DNA 
replication stress and CHK1 inhibitor. 
In addition, I also found that -H2AX is mainly expressed as well as Ser4/8 
hyper-phosphorylated RPA and p-p53 (S15) in thymidine treated hTERT-NHU 
cells following Chk1 inhibition by the inhibitor Gö6976. It is consistent with the 
fact that RPA is competent to associate with DNA damage foci and co-localize 
with -H2AX under DNA damage or DNA replication stress (Vassin et al., 
2004). 
 
-HA2X is generally considered as a marker of DNA double strand breaks 
(DSB). Following DSB, the histone subunit H2AX was rapidly (in 30 minutes) 
phosphorylated at c-terminus by one or more DSB-activated PI3K-like kinases 
including ATM, ATR and DNA-PK to form -H2AX at near DSB sites (Bonner et 
al., 2008; Rogakou et al., 1999). The growing -H2AX focus may serve to open 
up the chromatin structure and result in the accumulation of many checkpoint 
and DNA repair-associated proteins to promote DNA damage signa lling 
pathway and DNA repair (Kruhlak et al., 2006). However, as thymidine does 
not induce DNA damage or DNA double strand breaks (Bolderson et al., 2004), 
but delays the DNA replication folk progression, it is unclear why thymidine 
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treatment still caused -H2AX expression in the hTERT-NHU cells (Gagou et 
al., 2010). In addition to DSB, although H2AX is reported to be phosphorylated 
by ultraviolet C-activated ATR kinase activity in response to DNA 
single-stranded regions (Stiff et al., 2006), it has been demonstrated that ATR 
is not the major regulator in hTERT-NHU cells under DNA replication stress. 
Whether its expression is associated with stalled replication-induced folk 
regression and ATM activation needs further studies.  
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6.1.6 The novel role of ATM in cell cycle S-phase entry in 
hTERT-NHU cells. 
In my study, ATM is also found to be activated as an early event in response to 
thymidine-induced DNA replication stress. ATM has been reported as a key 
sensor in response to DNA double strand breaks (Lavin, 2007; Lavin and 
Kozlov, 2007; Niida and Nakanishi, 2006) or DNA ends (Bolderson et al., 2004).  
It is surprising to see that ATM inhibitor activation results in a G1 phase block 
that was revealed by a lack of S phase entry. Interestingly, autophagy-like 
morphological changes were observed, but other autophagy-like features were 
missing. Notably, ATM is reported to be necessary for the self-renewal of 
mouse haematopoietic stem cells by regulating oxidative stress (Block et al., 
2004). Whether the defect of cycle G1-S phase progression in normal urothelial 
cells results in some kind of cell re-programming needs further examination.  
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6.1.7 Limitations  
In this study, I have reported a novel role of CHK1 and ATM in immortalized 
hTERT-NHU cells. These findings seem to suggest an attractive new target for  
cancer therapy however there are still many details remain unclear. How the 
mechanism of Chk1 works, how ATM deficiency prevents G1/S phase 
transition in normal urothelial cells, why only Chk1 inhibited tumour cells take 
effect following replication stress are still poorly understood. Can this death 
response also apply to other bladder tumour cells in addition to EJ and 
TCC-sup? I have tried similar treatments on lower grade tumour cells such as 
RT4 or RT112, however less evidence of cell apoptosis was shown on those 
cell types. The cell death response is much lower than in more malignant 
Tcc-sup and EJ cells. In addition, I have found that activation of ATR-Chk1 
signalling cascades is deficient in response to DNA replication stress in 
hTERT-NHU cells by many clues. However I have not analysed yet ATR 
activation.  
 
The most important of all, transformed immortalized NHU cells are not totally 
normal ones. Unfortunately, primary normal human urothelial (NHU) cells were 
difficult to analyse. Unlike cancer cell lines, even immortalized hTERT-NHU 
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cells are really difficult to work with. Re-feed with the specific and expensive 
KSFM culture medium is needed three times per week. Additionally, they grow 
slowly and are unstable. Attempts to culture them in petri-dish for a long-term 
treatment have never seen successful. Furthermore, the Chk1 inhibitor 
Gö6976 is not extremely specific to Chk1 kinase, hence the Chk1 siRNA may 
be a good comparison to the inhibitor. I did attempt to deplete Chk1 with 
siRNAs but these experiments were unsuccessful. Generally groups here have 
not been successful with siRNA or shRNA mediated knockdowns of target 
genes in the hTERT-NHU cells.   
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6.1.8 Future work 
In addition to cell cycle checkpoint signalling, mitogen-activated protein kinase 
(MAPK) cascades are critical signalling pathways and well-known 
proto-oncogenes which regulate cell proliferation, survival and differentiation of 
both normal and malignant cells (Roberts and Der, 2007). Hence, it is not 
surprising that aberrant regulation of MAPK cascades contribute to cancer and 
other human diseases. Interestingly, exposure of various multiple myeloma 
cells to non-cytotoxic concentrations of Chk1 inhibitors induced DNA damage 
and a little cell death accompanied by Ras and ERK1/2 activation (Dai et al., 
2008; Dai et al., 2001). Furthermore, interruption of the MAPK signalling 
cascade also enhanced Chk1 inhibitor-induced DNA damage and apoptosis 
both in vitro and in vivo (Dai et al., 2008). Deregulated Ras signalling was 
found to compromise DNA damage checkpoint recovery after completing DNA 
repair in S. cerevisiae yeast. This indicated a new role for the Ras signalling 
pathway as a regulator of DNA damage checkpoint recovery (Wood and 
Sanchez, 2010). At the same time, the ATR-Chk1 pathway was shown to be 
able to limit oncogenic Ras transformation induced genomic instability. In 
cultured murine embryonic fibroblasts (MEFs), the observation of elevated 
genomic instability and synergistically increased lethality were found due to the 
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combination of ATR suppression and oncogenic Ras activation (Gilad et al., 
2010). However whether Chk1 suppression also affects MAPK pathway is still 
not clear. Together these studies, Ras/MEK/ERK signalling cascade may 
represent an interaction or functional compensation with Chk1 checkpoint 
signalling pathway. It would be interesting to examine the potential interaction 
between MAPK and ATM-Chk1 particularly in normal epithelial cells. 
 
In addition, to further examine whether the cell survival of hTERT-NHU cells in 
response to CHK1 inhibitor under DNA replication stress is ATR dependent or 
not, ATR inhibitor might be an interesting treatment especially combined with 
CHK1 inhibitor.  
 
Furthermore, DNA replication stress resulting from oncogene expression was 
shown to lead to genome instability in early cancer stage (Di Micco et al., 
2006). Overexpression of oncogenes such as HPV-16 E6/E7 and cyclin E has 
been demonstrated to lead to abnormal RB-E2F pathway which resulted in 
insufficient nucleotide pools during DNA replication and finally caused DNA 
damage and genome instability (Bester et al., 2011). Since the thymidine 
treatment in current step of this study also caused nucleotide pool unbalance 
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and deficiency and which was shown to be connected to checkpoint kinase 
activation. Hence, it would be interesting to make stable cell lines with different 
kind of oncogenes such as cyclin E, c-myc for mimicking the condition and 
investigate the potential role of checkpoint mechanism in early oncogenesis 
stages in normal epithelial cells. 
 
Additionally, directly examining the status of DNA strand in response to loss of 
ATM-Chk1 under DNA replication stress would be helpful to understand the 
detailed mechanism of how this system works and try to answer why only 
malignant tumour cells are selectively ki lled.  
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6.1.9 Conclusion 
Cancer is considered as one of the greatest death threats to human beings 
nowadays. Unfortunately there are still many difficulties on the way for beating 
cancer. Several newer types of treatment such as targeted therapy are now 
being studied. Many targeted drugs including sunitinib (Sutent® ), lapatinib 
(Tykerb® ), erlotinib (Tarceva® ), trastuzumab (Herceptin® ), and gefitinib (Iressa® )  
are already being used to treat different types of cancer. However the effect of 
these drugs on bladder tumours is not as good as on their original targets. In 
comparison to other solid tumors such as lung, breast and prostate, no 
targeted therapies for bladder cancer have brought to the clinic and there is no 
new agent being registered in the past two decades (Dovedi and Davies, 
2009). Recently, although some groups have also declared they find some 
new targets for targeted therapeutics, their treatments usually result in some 
side effects or irreversible cell senescence on normal cells. This work identified 
a huge different consequence of ATM/CHK1 inhibition between malignant and 
normal cells that the death response is specific to advanced cancer cells but 
not non-tumour urothelial cells under DNA replication stress. Whereas kinase 
activity-suppressed Chk1 only slowed S phase progression, ATM inhibition 
triggered p19 activation and down-regulated cyclin D1, CDK4 and p-RB in 
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hTERT-NHU cells (Fig. 6). These findings suggest that ATM and CHK1 
signalling cascades may be an attractive target for cancer therapy in the 
future. 
 
FIGURE6. Schematic representation of the different signalling 
transduction pathways in response to Chk1/ATM inhibitor in hTERT-NHU 
cells.  Whereas kinase activity-suppressed Chk1 only slowed S phase 
progression, ATM inhibition resulted in p19 activation and further 
down-regulated cyclin D1, CDK4 and p-RB, which triggered G1 checkpoint 
activation and prevented S phase entry in hTERT-NHU cells.    
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